var title_f21_4_21568="Hyperopia flat cornea";
var content_f21_4_21568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperopia with flat cornea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A flat cornea focuses light behind the retina resulting in hyperopia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21568=[""].join("\n");
var outline_f21_4_21568=null;
var title_f21_4_21569="UIP IPF radiographs";
var content_f21_4_21569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Idiopathic pulmonary fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 184px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Chest radiograph shows typical peripheral reticular opacity, most marked at the bases, with honeycombing. Lower lobe volume loss (not present in this case) is also common. Chest radiographs may occasionally be normal in patients with IPF. (B and C) CT images show basal predominant, peripheral predominant reticular abnormality with traction bronchiectasis and honeycombing, typical of IPF.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21569=[""].join("\n");
var outline_f21_4_21569=null;
var title_f21_4_21570="Moisture chambers use";
var content_f21_4_21570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moisture chamber in use",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21570=[""].join("\n");
var outline_f21_4_21570=null;
var title_f21_4_21571="Patient information: Mitral valve prolapse (The Basics)";
var content_f21_4_21571=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83799\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"         Chambers and valves of the heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/9/8340\">",
"          Mitral valve prolapse",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"           Transthoracic echocardiogram (echo)",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/48/26370\">",
"         Patient information: Endocarditis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/42/36514\">",
"         Patient information: Heart murmurs (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/60/19394\">",
"         Patient information: Mitral regurgitation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/23/11635\">",
"         Patient information: Prosthetic valves (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/39/34419\">",
"         Patient information: Sudden cardiac arrest (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/22/35170\">",
"         Patient information: Transient ischemic attack (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/37/31314\">",
"         Patient information: Antibiotics before procedures (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/59/27575\">",
"         Patient information: Mitral regurgitation (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/18/20772\">",
"         Patient information: Transient ischemic attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Mitral valve prolapse (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/mitral-valve-prolapse-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1667903847\">",
"      <span class=\"h1\">",
"       What is mitral valve prolapse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mitral valve prolapse is a condition in which one of the valves in the heart, called the mitral valve, doesn&rsquo;t close normally (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"UTD.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef83803 \" href=\"UTD.htm?8/9/8340\">",
"       figure 2",
"      </a>",
"      ). The mitral valve is made up of 2 flaps. In mitral valve prolapse, 1 or both flaps don&rsquo;t close in the correct way.",
"     </p>",
"     <p>",
"      When the heart valves work normally, they keep blood flowing in only 1 direction. The mitral valve normally keeps blood flowing from the left atrium to the left ventricle (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"UTD.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      When the mitral valve flaps don&rsquo;t close correctly, blood can leak backward in the wrong direction. When blood leaks backward from the left ventricle to the left atrium, doctors call it &ldquo;mitral regurgitation.&rdquo; Some patients with mitral valve prolapse have mitral regurgitation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667903896\">",
"      <span class=\"h1\">",
"       What causes mitral valve prolapse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mitral valve prolapse can happen on its own, because the valve can get damaged over time. It can also happen as a result of another medical condition. For example, &ldquo;connective-tissue diseases,&rdquo; which are diseases that affect certain tissues in the body, can cause mitral valve prolapse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667903911\">",
"      <span class=\"h1\">",
"       What are the symptoms of mitral valve prolapse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with mitral valve prolapse have no symptoms. Their doctor or nurse will find out they have it during an exam. The doctor or nurse will hear a &ldquo;click&rdquo; or heart murmur when he or she listens to the heart with a stethoscope. A heart murmur is an abnormal sound that often sounds like an extra &ldquo;whoosh&rdquo; or &ldquo;swish&rdquo; in the heartbeat.",
"     </p>",
"     <p>",
"      Some people with mitral valve prolapse have symptoms such as chest pain, feeling their heart beating fast or hard, fainting, or feeling dizzy. Even though these symptoms sometimes happen in people with mitral valve prolapse, these symptoms might not be caused by the mitral valve prolapse.",
"     </p>",
"     <p>",
"      Mitral valve prolapse can be mild or severe. It sometimes also leads to serious problems. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Mitral regurgitation &ndash; This usually causes no symptoms until it is severe.",
"       </li>",
"       <li>",
"        Endocarditis, which is when a heart valve gets infected &ndash; This can cause a fever and make people feel tired.",
"       </li>",
"       <li>",
"        Heart rhythm problems &ndash; Sometimes, this makes people feel as if their heart is beating fast or hard. Rarely, a heart rhythm problem can cause sudden death, which is when the heart suddenly stops beating.",
"       </li>",
"       <li>",
"        A stroke, which is when part of the brain is damaged because it goes without blood for too long",
"       </li>",
"       <li>",
"        A transient ischemic attack (called a &ldquo;TIA&rdquo;), which is similar to a stroke, but the brain isn&rsquo;t damaged",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667903926\">",
"      <span class=\"h1\">",
"       Is there a test for mitral valve prolapse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The test used most often to check for mitral valve prolapse is an echocardiogram (also called an &ldquo;echo&rdquo;). This test uses sound waves to create a picture of the heart as it beats. It shows the size of the heart chambers, how well the heart is pumping, and how well the heart valves are working (",
"      <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"       figure 3",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667903958\">",
"      <span class=\"h1\">",
"       How is mitral valve prolapse treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on how severe the mitral valve prolapse is and whether it is causing problems.",
"     </p>",
"     <p>",
"      People with mild mitral valve prolapse and mild mitral regurgitation might not need any treatment. But their doctor will follow their condition to see if it worsens and needs treatment later on.",
"     </p>",
"     <p>",
"      People with severe mitral regurgitation might need surgery. During surgery, the doctor will fix or replace the mitral valve.",
"     </p>",
"     <p>",
"      Other treatments some people with mitral valve prolapse might have include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines that lower blood pressure",
"       </li>",
"       <li>",
"        Medicines that treat heart rhythm problems",
"       </li>",
"       <li>",
"        Medicines that help prevent blood clots &ndash; These medicines might be used if people also have a heart rhythm problem called &ldquo;atrial fibrillation.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667903973\">",
"      <span class=\"h1\">",
"       Do I need to take antibiotics before I go to the dentist?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. In the past, doctors recommended that people with mitral valve prolapse take antibiotics before going to the dentist or having certain medical or dental procedures. But now, only people with certain heart conditions need antibiotics before going to the dentist or having a procedure. People with mitral valve prolapse do",
"      <strong>",
"       not",
"      </strong>",
"      need antibiotics for those times.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667903988\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor before you start trying. He or she will discuss the problems that might happen during your pregnancy. He or she might also need to change your medicines to ones that are safer to take during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667904003\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=see_link\">",
"       Patient information: Heart murmurs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       Patient information: Sudden cardiac arrest (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=see_link\">",
"       Patient information: Prosthetic valves (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=see_link\">",
"       Patient information: Mitral regurgitation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=see_link\">",
"       Patient information: Transient ischemic attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=see_link\">",
"       Patient information: Endocarditis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=see_link\">",
"       Patient information: Mitral regurgitation (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/37/31314?source=see_link\">",
"       Patient information: Antibiotics before procedures (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=see_link\">",
"       Patient information: Transient ischemic attack (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/4/21571?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83799 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21571=[""].join("\n");
var outline_f21_4_21571=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667903847\">",
"      What is mitral valve prolapse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667903896\">",
"      What causes mitral valve prolapse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667903911\">",
"      What are the symptoms of mitral valve prolapse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667903926\">",
"      Is there a test for mitral valve prolapse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667903958\">",
"      How is mitral valve prolapse treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667903973\">",
"      Do I need to take antibiotics before I go to the dentist?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667903988\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667904003\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"      Chambers and valves of the heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/9/8340\">",
"       Mitral valve prolapse",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"        Transthoracic echocardiogram (echo)",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/37/31314?source=related_link\">",
"      Patient information: Antibiotics before procedures (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=related_link\">",
"      Patient information: Endocarditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=related_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=related_link\">",
"      Patient information: Mitral regurgitation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=related_link\">",
"      Patient information: Transient ischemic attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=related_link\">",
"      Patient information: Transient ischemic attack (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_4_21572="Ioflupane I-123: Drug information";
var content_f21_4_21572=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ioflupane I-123: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/9/40083?source=see_link\">",
"    see \"Ioflupane I-123: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13374859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DaTscan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13374863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13374916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Thyroid protective agents (potassium iodide [SSKI] or Lugol's solution) equivalent to 100 mg iodide or 400 mg potassium perchlorate, should be given at least 1 hour prior to administration. Perform SPECT imaging 3-6 hours after ioflupane I 123 administration (see manufacturer&rsquo;s prescribing information for additional imaging information).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Radioimaging:",
"     </b>",
"     I.V.: 3-5 mCi (111-185 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13374917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13374919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"     <b>",
"      Note:",
"     </b>",
"     Ioflupane I 123 is renally excreted and patients with severe renal impairment may have increased radiation exposure and altered SPECT images.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13374918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13374925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DaTscan&trade;: Ioflupane 0.07-0.13 mcg and l 123 74 MBq (2 mCi) per 1 mL (2.5 mL) [contains ethanol 5%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13374861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F13374858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13374920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by slow I.V. injection over &ge;15 seconds via an arm vein. Begin SPECT imaging 3-6 hours following I.V. administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13374864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Striatal dopamine transporter (DaT) visualization using single photon emission computed tomography (SPECT) brain imaging as an adjunct to other diagnostic tests to assist in the evaluation of  patients with suspected Parkinsonian syndromes (PS); specifically, to differentiate essential tremor (ET) from tremor due to PS (idiopathic Parkinson&rsquo;s disease, multiple system atrophy, and progressive supranuclear palsy)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13374865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     DaT visualization using SPECT brain imaging as an adjunct to evaluate patients with suspected Creutzfeldt&ndash;Jakob disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15245846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13374900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &le;1% (Limited to important or life-threatening): Dizziness, headache, nausea, pruritus, rash, vertigo, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13374883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ioflupane, iodine, or any components of the formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13374884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Has been reported. Use extreme caution in patients with iodine or iodine contrast agent hypersensitivity. Appropriate equipment and emergency medications should be available during use. Hypersensitivity reactions primarily involved skin erythema and/or pruritus; reactions usually resolved spontaneously or following administration of corticosteroids and antihistamines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; ioflupane I 123 is eliminated renally. Therefore, patients with severe renal impairment may have increased radiation exposure and altered images. Effect of renal impairment on imaging with ioflupane I 123 has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: To limit thyroid gland accumulation of iodine 123 during exposure to ioflupane I 123, administer thyroid-blocking medications (eg, potassium iodide oral solutions, potassium perchlorate) at least 1 hour prior to administration; increased long-term risk for thyroid neoplasia can occur from failure to block thyroid uptake of iodine 123.",
"     <b>",
"      Note:",
"     </b>",
"     Avoid the use of potassium iodide oral solution or Lugol&rsquo;s solution in patients with past hypersensitivity to iodine or iodide products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Minimize radiation to bladder: Patients should be adequately hydrated prior to and following administration; instruct patients to void frequently for 48 hours following administration to decrease radiation exposure to bladder.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13462055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13462053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benztropine: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norepinephrine: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13374879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13374880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Radiopharmaceuticals have the potential to cause fetal harm and pregnancy should be ruled out prior to administration in women of reproductive age. Radioactive iodine crosses the placenta and may impair fetal thyroid function.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13374881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13374882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The radiolabeled component of ioflupane, iodine 123, is excreted into human milk, therefore, due to potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended. Consider interrupting breast-feeding (pumping and discarding) for 6 days after administration of ioflupane I 123 to minimize risk to infant.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DaTscan Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     185 mbq/2.5 mL (2.5 mL): $2851.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13374923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13374905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds reversibly to the dopamine transporter (DaT) with selectivity for the presynaptic sites in the striatum (caudate nucleus and putamen) of the human brain; the nuclear decay of the iodine 123 moiety emits gamma radiation, allowing visualization of receptor occupancy across tissues through SPECT imaging",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13374907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     DaTscan&trade; contains iodine-123 labeled ioflupane. The kinetics of the drug molecule ioflupane are not equivalent to the kinetics/half-life of  the radiolabeled ioflupane iodine 123. The kinetics presented correspond to the radioactive ioflupane I 123.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: ~7% of radioactivity in brain within 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of radioactivity: Striata to background ratios were constant between 3-6 hours after administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: ~30% of radioactivity from the whole brain attributed to striatal uptake",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Iodine 123: 13.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: At 48 hours postinjection: Urine (~60% ); fecal (~14%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hinnell C, Buxton-Thomas M, Sibtain N, et al, \"Striatal 123I-Ioflupane SPECT Abnormality in Sporadic Creutzfeldt&ndash;Jakob Disease,\"",
"      <i>",
"       J Neurol",
"      </i>",
"      , 2010, 258(5):948-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21572/abstract-text/21174113/pubmed\" id=\"21174113\" target=\"_blank\">",
"        21174113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mazzoleni R, Vanderheyden JE, Delcourt E, et al, \"123I-ioflupane SPECT Scan in a Patient With Creutzfeldt-Jakob Disease,\"",
"      <i>",
"       Acta Neurol Belg",
"      </i>",
"      , 2010, 110(1):118-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21572/abstract-text/20514941/pubmed\" id=\"20514941\" target=\"_blank\">",
"        20514941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ragno M, Scarcella MG, Cacchi&ograve; G, et al, \"Striatal [123I] FP-CIT SPECT Demonstrates Dopaminergic Deficit in a Sporadic Case of Creutzfeldt-Jakob Disease,\"",
"      <i>",
"       Acta Neurol Scand",
"      </i>",
"      , 2009, 119(2):131-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21572/abstract-text/18638039/pubmed\" id=\"18638039\" target=\"_blank\">",
"        18638039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tolosa E, Borght TV, and Moreno E, &ldquo;Accuracy of DaTSCAN (123I-Ioflupane) SPECT in Diagnosis of Patients With Clinically Uncertain Parkinsonism: 2-Year Follow-Up of an Open-Label Study,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2007, 22(16):2346-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21572/abstract-text/17914722/pubmed\" id=\"17914722\" target=\"_blank\">",
"        17914722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17072 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-83C710A96E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21572=[""].join("\n");
var outline_f21_4_21572=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374859\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374863\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374916\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374917\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374919\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374918\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374925\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374861\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374858\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374920\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374864\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374865\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245846\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374900\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374883\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374884\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13462055\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13462053\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374879\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374880\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374881\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374882\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322907\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374923\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374905\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374907\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17072|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/9/40083?source=related_link\">",
"      Ioflupane I-123: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_4_21573="Pramlintide: Patient drug information";
var content_f21_4_21573=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pramlintide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     see \"Pramlintide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      SymlinPen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe low blood sugar may happen when taking this drug with your insulin. Do not drive or use heavy machinery until you know the effects of this drug on your blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pramlintide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703834",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have slow stomach clearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you cannot tell when your blood sugar is low.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697647",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have had repeated low blood sugar or if you cannot feel or do not know the signs of very low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are taking any other drugs to speed up food clearing from your stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. This may get better once you are on a stable dose of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give this drug at some other site from where you gave your insulin if you are also getting insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694732",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not mix this drug in the same syringe with insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot right before a meal into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need to lower the dose of insulin you take, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696552",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Never make up a missed dose. Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for the next dose and you have already eaten, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696518",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you stop taking this drug, talk with your doctor. You may need to be restarted at a lower dose and raise the dose slowly.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699571",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened vials and pens in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened vials and pens at room temperature or in a refrigerator. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened vials and pens from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect vials and pens from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11351 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C08C8C0CB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21573=[""].join("\n");
var outline_f21_4_21573=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212375\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018758\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018760\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018759\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018764\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018765\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018767\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018762\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018763\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018768\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018769\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=related_link\">",
"      Pramlintide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_4_21574="Normal intracardiac electrograms";
var content_f21_4_21574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Normal intracardiac electrograms obtained during invasive electrophysiologic study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 620px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal intracardiac electrograms, during sinus rhythm, obtained during an electrophysiologic study are shown. Three surface ECG leads are monitored (I, aVF, and V1); intracardiac eelctrograms are obtained from the high right atrium (HRA); the proximal (p), mid (m) , and distal (d) bundle of His (HBE); the p, m, and d coronary sinus (CS); and right ventricular apex (RVA). For an ablation procedure, and exploratory catheter (exp) is also used for more extensive mapping. The electrogram obtained include those from the atrium (A), bundle of His (H), ventricle (V).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21574=[""].join("\n");
var outline_f21_4_21574=null;
var title_f21_4_21575="Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology";
var content_f21_4_21575=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/4/21575/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21575/contributors\">",
"     Mark R Proctor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/4/21575/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21575/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/4/21575/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21575/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/4/21575/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural hematoma (SDH) forms when there is hemorrhage into the potential space between the dura and the arachnoid membranes. SDH in children differs significantly from SDH in adults because inflicted head injury is a common etiology, especially in pediatric patients under two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast to epidural hematoma (EDH), indications for operative management of SDH are less clear, and surgery is less likely to prevent morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=see_link\">",
"     \"Intracranial subdural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will discuss the epidemiology, anatomy, and pathophysiology of subdural hematoma in children. The clinical features, evaluation, and management of SDH in children and SDH in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=see_link\">",
"     \"Intracranial subdural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=see_link\">",
"     \"Subdural hematoma in adults: Prognosis and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rapid overview summarizes the important clinical features and initial management of SDH in children (",
"    <a class=\"graphic graphic_table graphicRef82616 \" href=\"UTD.htm?25/3/25660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of SDH in children varies by age. SDH occurs most frequently in infants and toddlers less than two years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;SDH may occur in up to 8 percent of term deliveries and appears to be associated with delivery by vacuum extraction or forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/2\">",
"     2",
"    </a>",
"    ]. These hematomas are typically small and usually resolve within four weeks. They are usually asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infants and toddlers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of SDH in young children under two years of age approaches 13 cases per 100,000 child-years with a higher incidence in infants (&le;1 year of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Inflicted head trauma accounts for the majority of SDH found in these children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Older children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motor vehicle collision (MVC) or other forms of major unintentional head trauma cause most traumatic brain injury, including SDH, in older children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;SDH occurs in the potential space between the dura and the arachnoid. Under normal conditions, the subdural region does not exist as a separate layer, unlike the subarachnoid space [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Site of hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major sources of bleeding in patients with SDH: bridging blood vessels that cross the subdural space and cerebral cortical hemorrhage caused by direct brain trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Subdural hematoma location",
"    </span>",
"    &nbsp;&mdash;&nbsp;SDH can appear in any intracranial location. Chronic hematomas in the higher convexities are associated with brain sag as gravity assists the brain separating from the dura. SDH associated with severe head injury is often located along the convexities of the frontal, parietal, and temporal lobes where tearing of bridging vessels and traumatic impact between the brain and the skull occurs. SDH seen in the interhemispheric space or posterior fossa highly suggests inflicted injury, as do hematomas in multiple sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Subdural and epidural hematoma anatomic comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key differences between SDH and epidural hematoma (EDH) are readily demonstrated by unenhanced head CT or by pathologic specimens. EDH, which is located in the potential space between dura and skull, does not cross the tight dural attachments at the cranial sutures. Consequentially, EDH characteristically has a lens-shaped, convex appearance and is limited in scope (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79566 \" href=\"UTD.htm?25/52/26432\">",
"     image 1",
"    </a>",
"    ). SDH can cross cranial suture margins but is limited by internal dural attachments, such as the falx and tentorium, and therefore typically appears as a crescent-shaped or concave extraaxial lesion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74235 \" href=\"UTD.htm?36/22/37231\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Blood vessel injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of closed head injury, rotational force can produce injury to veins, arteries, or brain parenchyma, resulting in SDH, epidural hematoma, or coup-countercoup contusions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/8\">",
"     8",
"    </a>",
"    ]. In young children with inflicted head injury, vigorous shaking, with or without a direct blow, causes shearing of white upon gray matter and disruption of bridging vessels caused by violent movement of the brain within the skull [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Venous hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute SDH is usually caused by tearing of the bridging veins that drain from the surface of the brain to the dural sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/10\">",
"     10",
"    </a>",
"    ]. Rupture of these vessels allows for bleeding into the space between the arachnoid membranes and dura through which the vessels traverse. Venous bleeding is usually arrested by the rising intracranial pressure or direct compression by the clot itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Arterial hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial rupture can also result in SDH, and this source accounts for approximately 20 to 30 percent of adult SDH cases. Most arterial SDHs arise from injuries to small cortical arteries of &lt;1 mm diameter. In adults, both arterial and venous SDHs have generally similar postmortem characteristics, although SDHs caused by arterial rupture are predominately located in the temporoparietal region, while those caused by bridging vein rupture are predominately frontoparietal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=see_link&amp;anchor=H2#H2\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dural traction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low cerebrospinal fluid (CSF) pressure (intracranial hypotension) is another mechanism that can result in SDH. Intracranial hypotension is typically caused by a spontaneous or iatrogenic cerebrospinal fluid leak, as may occur following ventricular peritoneal shunting for hydrocephalus in children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/11\">",
"     11",
"    </a>",
"    ]. As the cerebrospinal fluid pressure decreases, there is a reduction in the buoyancy of the brain, causing traction on the anchoring and supporting structures, including the dura. Traction on bridging veins can cause tearing and rupture of these vessels, while intracranial hypotension itself leads to engorgement of cerebral veins and subsequent leakage of fluid into the subdural space. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Increased intracranial pressure (ICP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with closed sutures, the intracranial compartment is protected by the skull, a rigid structure with a fixed internal volume; the intracranial contents include (by volume) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brain parenchyma - 80 percent",
"     </li>",
"     <li>",
"      Cerebrospinal fluid (CSF) - 10 percent",
"     </li>",
"     <li>",
"      Blood - 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ICP is a function of the volume and compliance of each component of the intracranial compartment, an interrelationship recognized over 150 years ago and known as the Monro-Kellie doctrine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Because the overall volume of the cranial vault cannot change in children with closed sutures, an increase in the volume of one component, or the presence of pathologic components, necessitates the displacement of other structures, an increase in ICP, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/12,14-17\">",
"     12,14-17",
"    </a>",
"    ]. With an expanding SDH, CSF, intracranial venous blood, and then brain parenchyma are displaced. If the SDH continues to increase in size, then death due to brain herniation through the foramen magnum ensues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This pathophysiology does not necessarily apply in young children because the sutures of the skull remain open until approximately 18 months of age. As a result, they tend to tolerate an expanding SDH better than older children or adults. There may also be age dependent responses to the SDH with younger brains being somewhat resistant to injury from the hematoma alone, but susceptible to other insults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=see_link&amp;anchor=H5#H5\">",
"     \"Trauma management: Unique pediatric considerations\", section on 'Brain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the capacity for large volume intracranial bleeding, young infants may become anemic from hemorrhage before showing objective signs of increased ICP (eg, altered mental status, seizures, pupillary changes, vomiting).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Type of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The source of bleeding and amount of associated brain injury correlate with the type of head trauma that produces a SDH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Severe head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;After severe head injury (eg, motor vehicle collision), hemorrhage arises from bridging vessels and an extensively damaged cerebral cortex. The subdural may be very small on radiographic imaging, but accompanies clinical and radiographic signs of severe diffuse brain injury. In this setting, the expected morbidity and mortality is higher than for patients with SDH and minor head injury, even though the size of the hematoma in children with minor head injury is often larger. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Minor head injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    SDH after major trauma typically has a worse prognosis than epidural hematoma (EDH) because of the associated extensive brain damage. Although EDH can cause rapid deterioration if not detected and treated, EDH is typically associated with little to no direct brain injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Inflicted head injury (shaken baby syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to SDH, acceleration-deceleration forces cause diffuse brain injury in victims of shaken baby syndrome. The susceptibility of infants to shaking injury arises from the relatively large size of the head, the weakness of the cervical musculature, softness of the skull, and high water content of the brain caused by incomplete myelination. The role of a direct blow as a major cause of injury in shaken babies is controversial. Associated injuries include retinal hemorrhage and fractures of the skull and skeleton. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link&amp;anchor=H4#H4\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\", section on 'Mechanisms of injury'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In victims of inflicted head trauma, hypoxic-ischemic injury frequently accompanies severe brain injury and hemorrhage because appropriate medical care is not immediately sought by the perpetrator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Minor head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of blood vessels (generally veins) crossing the subdural space is the prime source of hemorrhage following minor head injury. The SDH in this instance can become large, with few clinical findings because the hematoma typically accumulates slowly and without serious direct brain injury. Patient susceptibility to hematoma formation is common. Predisposing factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dural traction or brain sag (eg, treated hydrocephalic patients or those with brain atrophy) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Subdural hygroma or chronic subdural effusion occurring after an acute SDH or meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/4,19-21\">",
"       4,19-21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Enlargement of the subarachnoid spaces (eg, benign extra-axial fluid of infancy) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61410 \" href=\"UTD.htm?9/35/9782\">",
"       image 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bleeding tendency (eg, thrombocytopenia, hemophilia, patients receiving anticoagulants, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      or Coumadin) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Osteogenesis imperfecta [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Glutaric aciduria, type 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rupture of an arachnoid cyst resulting in intracystic hemorrhage and subdural hematoma [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/26-29\">",
"       26-29",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At times the distinction between posttraumatic SDH and enlargement of the subarachnoid space is difficult. Radiographic imaging can assist in making this important determination [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=see_link&amp;anchor=H11#H11\">",
"     \"Intracranial subdural hematoma in children: Clinical features, evaluation, and management\", section on 'Radiographic imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic subdural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial meningeal trauma and development of SDH, dural collagen synthesis is induced and fibroblasts spread over the inner surface of the dura to form a thick outer membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Subsequently, a thinner inner membrane develops, resulting in complete encapsulation of the clot. This occurs over a predictable time course of approximately two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/31\">",
"     31",
"    </a>",
"    ]. This ability to time chronic SDH is often used as forensic evidence that establishes child abuse in cases of inflicted head injury (shaken baby syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link&amp;anchor=H8#H8\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\", section on 'Subdural hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over time, a chronic SDH may liquefy, or form a hygroma, and the membranes may calcify [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/31\">",
"     31",
"    </a>",
"    ]. More than one-half of all SDHs liquefy and tend to enlarge as opposed to remaining solid and stable in size [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/10\">",
"     10",
"    </a>",
"    ]. Although the reason for this observation is unknown, a larger initial clot size appears to be related to a greater likelihood of subsequent expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At any time, the hematoma may expand secondary to recurrent bleeding (\"acute-on-chronic\" SDH) or from osmotic draw of water into the hygroma, owing to its high protein content. Cerebral hemisphere lesions and secondary brainstem injury may develop as a consequence of the mass effect produced by a large SDH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Subdural hygroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural hygromas are thought to develop passively as a consequence of traumatic brain injury followed by brain atrophy, dehydration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased intracranial pressure. The mechanism of hygroma formation in this setting is related to the separation of the arachnoid layer from the dura, which can occur when a contracting brain pulls the arachnoid along with it while the dura remains adherent to the skull [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most subdural hygromas will resolve with adequate reexpansion of the intracranial contents (eg, hydration). However, some will become chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21575/abstract/33\">",
"     33",
"    </a>",
"    ]. The persistence of hygromas appears to be related to the formation of pseudomembranes (as discussed above) that line the space created between the arachnoid and the dura during the acute phase. These subsequently become vascularized by abnormally permeable capillaries that allow for further accumulation of subdural fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features, evaluation, and management of SDH in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=see_link\">",
"     \"Intracranial subdural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among children, SDH develops most frequently in infants and toddlers (&le;2 years of age). Inflicted head injury (shaken baby syndrome) is the most common cause in this age group. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"       \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subdural hematoma (SDH) occurs in the potential space between the dura and the arachnoid. Bleeding arises from rupture of bridging blood vessels and, when associated with severe head trauma, from an extensively damaged cerebral cortex. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Site of hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SDH can cross suture margins, but is limited by internal dural attachments such as the falx cerebri and tentorium cerebelli and therefore typically appears as a crescent-shaped or concave extraaxial lesion on unenhanced computed tomography (CT) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74235 \" href=\"UTD.htm?36/22/37231\">",
"       image 2",
"      </a>",
"      ). In contrast, epidural hematoma crosses internal dural attachments but does not cross suture lines. Thus, EDH characteristically has a lens-shaped, convex appearance on head CT (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79566 \" href=\"UTD.htm?25/52/26432\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Subdural and epidural hematoma anatomic comparison'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood vessel injury in children with SDH following major trauma (inflicted and unintentional) may involve veins or arteries. In young children with inflicted head injury, vigorous shaking, with or without a direct blow, causes extensive bleeding from the brain cortex in addition to bridging vessel rupture during violent movement of the brain within the skull. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Blood vessel injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An expanding SDH causes increased intracranial pressure (ICP) in children with closed sutures and without prompt intervention may result in death due to brain herniation. The impact of increased ICP from SDH may be blunted in young children with open cranial sutures. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Increased intracranial pressure (ICP)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"       \"Elevated intracranial pressure in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=see_link&amp;anchor=H15#H15\">",
"       \"Intracranial subdural hematoma in children: Clinical features, evaluation, and management\", section on 'Definitive management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The type of traumatic brain insult and the associated brain injury largely determine the clinical severity of a SDH. The size of the hematoma is less important. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Type of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with bleeding tendency, dural traction, enlarged subarachnoid spaces, osteogenesis imperfecta, and glutaric aciduria type I are at increased risk of SDH following minor head injury. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Minor head injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic subdural fluid collections containing clotted blood or proteinaceous fluid commonly develop after a SDH. Membrane formation in chronic SDH predictably occurs two weeks after injury. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Chronic subdural hematoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Subdural hygroma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Proctor, MB, MC. Neurosurgical aspects of non-accidental trauma in children. In: Neurological Surgery Principles and Practice, Loftus, B (Eds), Lippincott Williams and Wilkins, Philadelphia 2003. p.1065.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/2\">",
"      Whitby EH, Griffiths PD, Rutter S, et al. Frequency and natural history of subdural haemorrhages in babies and relation to obstetric factors. Lancet 2004; 363:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/3\">",
"      Jayawant S, Rawlinson A, Gibbon F, et al. Subdural haemorrhages in infants: population based study. BMJ 1998; 317:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/4\">",
"      Hobbs C, Childs AM, Wynne J, et al. Subdural haematoma and effusion in infancy: an epidemiological study. Arch Dis Child 2005; 90:952.",
"     </a>",
"    </li>",
"    <li>",
"     Langlois JA, Rutland-Brown W, Thomas KE. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/6\">",
"      Haines DE, Harkey HL, al-Mefty O. The \"subdural\" space: a new look at an outdated concept. Neurosurgery 1993; 32:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/7\">",
"      Yamashima T, Friede RL. Why do bridging veins rupture into the virtual subdural space? J Neurol Neurosurg Psychiatry 1984; 47:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/8\">",
"      Besenski N. Traumatic injuries: imaging of head injuries. Eur Radiol 2002; 12:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/9\">",
"      Duhaime AC, Gennarelli TA, Thibault LE, et al. The shaken baby syndrome. A clinical, pathological, and biomechanical study. J Neurosurg 1987; 66:409.",
"     </a>",
"    </li>",
"    <li>",
"     Victor, M, Ropper, A. Craniocerebral trauma. In: Adams and Victor's Principles of Neurology, 7th, Victor, M, Ropper, A (Eds), McGraw-Hill, New York 2001. p.925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/11\">",
"      Kim BS, Jallo GI, Kothbauer K, Abbott IR. Chronic subdural hematoma as a complication of endoscopic third ventriculostomy. Surg Neurol 2004; 62:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/12\">",
"      Allen CH, Ward JD. An evidence-based approach to management of increased intracranial pressure. Crit Care Clin 1998; 14:485.",
"     </a>",
"    </li>",
"    <li>",
"     Monro A. Observations on the Structure and Functions of the Nervous System, Creech and Johnson, Edinburgh 1783.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/14\">",
"      Kellie, G. An account of the appearances observed in the dissection of two of the individuals presumed to have perished in the storm of the third, and whose bodies were discovered in the vicinity of Leith on the morning of the 4th November 1821; with some reflections on the pathology of the brain. Trans Med Chir Soc (Edinburgh) 1821-1832; 1:84.",
"     </a>",
"    </li>",
"    <li>",
"     Steele, DW. Neurosurgical emergencies, nontraumatic. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1717.",
"    </li>",
"    <li>",
"     Poss, WB, Brockmeyer, DL, Clay, B, Dean, JM. Pathophysiology and management of the intracranial vault. In: Textbook of Pediatric Intensive Care, Rogers, MC (Eds), Williams &amp; Wilkins, Baltimore 1996. p.645.",
"    </li>",
"    <li>",
"     Greenes, DS. Neurotrauma. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1361.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/18\">",
"      Durham SR, Duhaime AC. Basic science; maturation-dependent response of the immature brain to experimental subdural hematoma. J Neurotrauma 2007; 24:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/19\">",
"      Carmel PW, Albright AL, Adelson PD, et al. Incidence and management of subdural hematoma/hygroma with variable- and fixed-pressure differential valves: a randomized, controlled study of programmable compared with conventional valves. , , , , , , , . Neurosurg Focus 1999; 7:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/20\">",
"      Swift DM, McBride L. Chronic subdural hematoma in children. Neurosurg Clin N Am 2000; 11:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/21\">",
"      Vinchon M, Joriot S, Jissendi-Tchofo P, Dhellemmes P. Postmeningitis subdural fluid collection in infants: changing pattern and indications for surgery. J Neurosurg 2006; 104:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/22\">",
"      McNeely PD, Atkinson JD, Saigal G, et al. Subdural hematomas in infants with benign enlargement of the subarachnoid spaces are not pathognomonic for child abuse. AJNR Am J Neuroradiol 2006; 27:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/23\">",
"      Pittman T. Significance of a subdural hematoma in a child with external hydrocephalus. Pediatr Neurosurg 2003; 39:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/24\">",
"      Sasaki-Adams D, Kulkarni A, Rutka J, et al. Neurosurgical implications of osteogenesis imperfecta in children. Report of 4 cases. J Neurosurg Pediatr 2008; 1:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/25\">",
"      Bishop FS, Liu JK, McCall TD, Brockmeyer DL. Glutaric aciduria type 1 presenting as bilateral subdural hematomas mimicking nonaccidental trauma. Case report and review of the literature. J Neurosurg 2007; 106:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/26\">",
"      Donaldson JW, Edwards-Brown M, Luerssen TG. Arachnoid cyst rupture with concurrent subdural hygroma. Pediatr Neurosurg 2000; 32:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/27\">",
"      Mori K, Yamamoto T, Horinaka N, Maeda M. Arachnoid cyst is a risk factor for chronic subdural hematoma in juveniles: twelve cases of chronic subdural hematoma associated with arachnoid cyst. J Neurotrauma 2002; 19:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/28\">",
"      Parsch CS, Krauss J, Hofmann E, et al. Arachnoid cysts associated with subdural hematomas and hygromas: analysis of 16 cases, long-term follow-up, and review of the literature. Neurosurgery 1997; 40:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/29\">",
"      Hopkin J, Mamourian A, Lollis S, Duhaime T. The next extreme sport? Subdural haematoma in a patient with arachnoid cyst after head shaking competition. Br J Neurosurg 2006; 20:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/30\">",
"      Sajanti J, Majamaa K. High concentrations of procollagen propeptides in chronic subdural haematoma and effusion. J Neurol Neurosurg Psychiatry 2003; 74:522.",
"     </a>",
"    </li>",
"    <li>",
"     Mayer, S, Rowland, L. Head injury. In: Merritt's Neurology, Rowland, L (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.401.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/32\">",
"      Labadie EL, Glover D. Physiopathogenesis of subdural hematomas. Part 1: Histological and biochemical comparisons of subcutaneous hematoma in rats with subdural hematoma in man. J Neurosurg 1976; 45:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21575/abstract/33\">",
"      Lee KS. The pathogenesis and clinical significance of traumatic subdural hygroma. Brain Inj 1998; 12:595.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6520 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21575=[""].join("\n");
var outline_f21_4_21575=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infants and toddlers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Older children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Site of hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Subdural hematoma location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Subdural and epidural hematoma anatomic comparison",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Blood vessel injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Venous hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Arterial hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dural traction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Increased intracranial pressure (ICP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Type of injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Severe head injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Inflicted head injury (shaken baby syndrome)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Minor head injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic subdural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Subdural hygroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6520|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/52/26432\" title=\"diagnostic image 1\">",
"      Epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/22/37231\" title=\"diagnostic image 2\">",
"      Subdural hematoma in an infant with mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/35/9782\" title=\"diagnostic image 3\">",
"      Pediatric subdural hematoma on magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6520|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/3/25660\" title=\"table 1\">",
"      Subdural hematoma children rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=related_link\">",
"      Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=related_link\">",
"      Intracranial subdural hematoma in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=related_link\">",
"      Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=related_link\">",
"      Subdural hematoma in adults: Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=related_link\">",
"      Trauma management: Unique pediatric considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_4_21576="Sucking and swallowing disorders in the newborn";
var content_f21_4_21576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sucking and swallowing disorders in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/4/21576/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21576/contributors\">",
"     Chantal Lau, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/4/21576/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21576/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/4/21576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21576/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/4/21576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to feed by mouth is critical for newborns. Healthy term infants readily take to the breast or bottle immediately after birth. Preterm infants must be fed by naso or oro-gastric tube until they develop the ability to feed orally. Infants with medical complications may require an alternative to oral feeding even after hospital discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27765?source=see_link\">",
"     \"Discharge planning for high-risk newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Safe and successful oral feeding depends upon the proper development of sucking, swallowing, and breathing, and their coordination in order to minimize oxygen desaturation, apnea, bradycardia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspiration, and enhance feeding efficiency. Because of methodologic limitations, these processes have been studied primarily during bottle feeding. However, mechanisms involved in bottle feeding are likely to apply to breastfeeding as well [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the physiology and development of sucking, swallowing, respiration, and their coordinated activities, as well as feeding disorders, including their management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUCKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sucking requires appropriate integration and timing of movements of the lips, cheeks, tongue, and palate in order to draw milk into the mouth, form a bolus, and propel it to the back of the pharynx to initiate the swallowing reflex [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/3\">",
"     3",
"    </a>",
"    ]. The activity of the oropharyngeal muscles must be coordinated to protect the airway and the nasal passages as the bolus travels to the esophagus.",
"   </p>",
"   <p>",
"    In healthy term infants, mature sucking consists of a rhythmic alternation between suction and expression (",
"    <a class=\"graphic graphic_waveform graphicRef72871 \" href=\"UTD.htm?22/21/22866\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Suction corresponds to the negative intraoral pressure exerted by the infant when milk is drawn into the mouth, while expression corresponds to the positive pressure resulting from mouthing, stripping,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    compression of the nipple between the tongue and the hard palate to eject milk from the nipple [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/1,5-7\">",
"     1,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sequential activation of the perioral muscles, including the temporal, masseter, orbicular, and suprahyoid muscles, is tightly correlated with the generation of suction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/8\">",
"     8",
"    </a>",
"    ]. Appropriate synchronization of the lingual musculature is necessary for the proper generation of expression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two types of sucking are recognized: nutritive and nonnutritive. Nutritive sucking occurs during feeding, while nonnutritive sucking occurs without transfer of milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nutritive sucking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritive sucking involves the transfer of milk in the course of feeding. The earliest postmenstrual age at which preterm infants can successfully take oral feedings is uncertain. It is customary to introduce oral feedings at approximately 33 to 34 postmenstrual weeks, when the sucking pattern appears similar to that of term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, wide variability exists for individual infants. Gestational age at birth and other medical problems likely contribute to this variance.",
"   </p>",
"   <p>",
"    Feeding performance can be monitored by simultaneous measurement of the infant's sucking maturity and the amount of milk consumed in a specified time, often 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/4,5,12\">",
"     4,5,12",
"    </a>",
"    ]. Sucking maturation has been evaluated by monitoring nutritive sucking pattern during bottle feeding.",
"   </p>",
"   <p>",
"    A five-point scale has been developed based on the presence or absence of suction and the rhythmicity of the suction and expression components (",
"    <a class=\"graphic graphic_figure graphicRef76540 \" href=\"UTD.htm?17/1/17428\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/13\">",
"     13",
"    </a>",
"    ]. This scale can assist in the evaluation of sucking skills in infants with feeding difficulties, but it is not universally available.",
"   </p>",
"   <p>",
"    Oral feeding performance, assessed by the volume transferred and rate of feeding, improves as sucking skills mature [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/13\">",
"     13",
"    </a>",
"    ]. Using the five-point scale, immature sucking is characterized by the use of the expression component only",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by arrhythmic suction and expression. With maturation, the alternation of suction and expression gains in rhythmicity and amplitude. Faster feeding results from this more efficient sucking pattern",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from increased duration of sucking bursts, amplitude, or frequency of sucking. However, oral feeding can be successful with immature sucking consisting of expression alone, but it is not as efficient [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/5,13\">",
"     5,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a study of 16 medically stable infants (gestational age 26 to 29 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/14\">",
"     14",
"    </a>",
"    ]. Longitudinal evaluation started at a mean age of 34 weeks gestation when the infants were taking one to two oral feeds a day and continued until the infants were taking six to eight oral feedings per day. Rate of milk intake advanced with postmenstrual age and maturation of sucking, which was characterized by an increased suction strength and activation speed of the suction musculature.",
"   </p>",
"   <p>",
"    Infants may be able to bottle feed before they can successfully breast feed, because with breastfeeding, suction is necessary to draw milk into the mouth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevent retraction of the teat. It is not needed for bottle feeding, as milk continuously fills the nipple chamber and the nipple is more rigid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/5\">",
"     5",
"    </a>",
"    ]. This is supported by the observation that oral feeding can be successful with expression alone, as mentioned above.",
"   </p>",
"   <p>",
"    Another study described an assessment tool based on proficiency of the oral feeding (percent volume in mL taken during the first five",
"    <span class=\"nowrap\">",
"     minutes/total",
"    </span>",
"    mL prescribed) and rate of milk transfer over the entire feeding",
"    <span class=\"nowrap\">",
"     (mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/15\">",
"     15",
"    </a>",
"    ]. This evaluation, which does not require special equipment and needs further validation, may help caretakers monitor infants&rsquo; skills as they transition to oral feeding and identify oral feeding issues arising from immature skills",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor endurance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonnutritive sucking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonnutritive sucking occurs when the infant sucks on a pacifier or finger, and no milk is transferred. The pattern is similar to nutritive sucking, but sucking and pause bursts are briefer and sucking frequency is faster (2 versus 1",
"    <span class=\"nowrap\">",
"     sucks/sec,",
"    </span>",
"    respectively) (",
"    <a class=\"graphic graphic_waveform graphicRef80145 \" href=\"UTD.htm?26/35/27184\">",
"     waveform 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/10\">",
"     10",
"    </a>",
"    ]. Nonnutritive sucking matures earlier than nutritive sucking [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonnutritive sucking reduces stress, and promotes weight gain and gastrointestinal maturation and growth. However, it has not been shown to increase the secretion of gastrointestinal hormones, such as gastrin, motilin, insulin, or insulin growth factor-I (IGF-I) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/17-24\">",
"     17-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In preterm infants, nonnutritive sucking prior to nipple feeding appears to enhance the transition from tube to oral feeding, possibly by affecting behavioral state. In one study, nonnutritive sucking for 10 minutes prior to nipple feeding resulted in fewer behavioral state changes and more quiet awake periods during feeding compared to no intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/25\">",
"     25",
"    </a>",
"    ]. In a prospective observational study, premature infants born between 25 and 35 weeks gestation with a more organized nonnutritive sucking patterns reached independent oral feeding earlier than those with a more chaotic pattern of sucking [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonnutritive sucking may not be a good indicator of an infant's ability to feed orally because, as swallowing is minimal, it does not require the same level of suck-swallow-breathe coordination needed for safe oral feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/16,27\">",
"     16,27",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_waveform graphicRef80145 \" href=\"UTD.htm?26/35/27184\">",
"     waveform 2",
"    </a>",
"    ). Orocutaneous stimulation using a novel motorized 'pulsating' pacifier has been shown to improve oral feeding in preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SWALLOWING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safe swallowing requires the proper coordination of movement of oropharyngeal structures, including the tongue, soft palate, pharynx, larynx, and esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/3,29,30\">",
"     3,29,30",
"    </a>",
"    ]. With maturation, swallowing becomes more adaptable, as it can handle larger bolus volumes and varying textures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/31\">",
"     31",
"    </a>",
"    ]. Head or neck positioning also becomes less critical for safe swallowing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Muscle activity for sucking and swallowing is innervated through branches of cranial nerves V, VII, IX, X, and XII. Their rhythmic activity is similar to that of respiration, suggesting that they may be controlled by a central rhythm pattern generator in the brainstem, located in the vicinity of the respiratory center [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/3,32-34\">",
"     3,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In mature individuals, swallowing can be involuntary or voluntary and controlled by higher cortical centers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In infants, an external input, such as a milk bolus, may be required to stimulate the swallowing center [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/37\">",
"     37",
"    </a>",
"    ]. The observation that swallowing is minimal during non-nutritive sucking, when no liquid is transferred, also supports the need for external stimuli.",
"   </p>",
"   <p>",
"    Swallowing is composed of an oral, pharyngeal, and esophageal phase, each involving the participation of different anatomical structures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/30\">",
"     30",
"    </a>",
"    ]. During the oral phase, the bolus is formed in the oral cavity. It is transported to the upper esophageal sphincter during the pharyngeal phase, and down to the stomach during the esophageal phase.",
"   </p>",
"   <p>",
"    In premature infants, pro-pharyngeal immaturity presents with poor bolus formation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lack of synchrony in the initiation of the swallowing reflex, laryngeal closure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    esophageal opening. These can lead to aspiration of milk before, during, or after a swallow as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improper formation of a bolus during the oral motor phase may result in liquid pushed into the oropharyngeal region while the trachea is open.",
"     </li>",
"     <li>",
"      Improper closure of the larynx during swallowing may result in liquid penetration into the trachea.",
"     </li>",
"     <li>",
"      Residual liquid in the valleculae and pyriform sinuses may lead to aspiration when the larynx reopens after the swallow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Esophageal immaturity can lead to decreased pharyngoesophageal transport of the bolus due to the poor timing of the contraction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    relaxation of the upper and lower esophageal sphincters during the passage of a bolus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immature esophageal motility is also likely to occur in preterm infants. Motility patterns are divided into peristaltic and nonperistaltic contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Peristalsis can be propagating in an ante- or retro-grade direction, whereas nonperistalsis describes synchronous contractions or incomplete peristalsis. Studies on preterm infants born between 25 to 35 weeks gestation and monitored between 33 and 38 weeks postmenstrual age showed significantly less propagating peristaltic than nonperistaltic motor patterns (27 versus 73 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal swallowing or dysphagia may also be the result of inappropriate esophageal motility [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In one study, dysphagic preterm infants diagnosed by an abnormal videofluoroscopic modified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    study, presented with dysfunctional pharyngoesophageal motility similar to that seen in infants with gastroschisis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Findings included infrequent swallows, failure of complete peristaltic propagation, prolonged distal esophageal waveforms, higher upper esophageal sphincter tone, and prolonged relaxation.",
"   </p>",
"   <p>",
"    The differences in the maturation processes implicated in the proximal striated and distal smooth regions may reflect the maturation of central and peripheral neuromotor mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of swallowing may be dependent upon the nature of the stimuli. This was illustrated in one study of 10 neonates with a postmenstrual age of 39 weeks evaluated by pharyngo-upper esophageal manometry while receiving air or sterile water infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/46\">",
"     46",
"    </a>",
"    ]. Both air and water can stimulate pharyngeal reflux swallowing. However, the response rate was greater with water compared to air infusions (76 versus 30 percent) and rose with increasing volume of water. In contrast, there was no difference between the two stimuli in the contractility of the pharyngo-upper esophageal sphincter. These findings may have implications for infants evaluated for swallowing, as air stimuli may result in fewer swallows to assess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUCK-SWALLOW-BREATH COORDINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper coordination of sucking, swallowing, and breathing facilitates gas exchange and minimizes the risk of aspiration (",
"    <a class=\"graphic graphic_waveform graphicRef72871 \" href=\"UTD.htm?22/21/22866\">",
"     waveform 1",
"    </a>",
"    ). Lack of coordination may result in disorders, including aspiration, oxygen desaturation, apnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/3,47-49\">",
"     3,47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During oral feeding, the sucking rhythm appears to entrain the swallowing rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/37\">",
"     37",
"    </a>",
"    ]. Respiratory and sucking activities appear independent from each other during non-nutritive sucking when swallowing is minimally implicated.",
"   </p>",
"   <p>",
"    Swallowing can occur at any time in the respiratory cycle, although in adults, it occurs most often during expiration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. This likely decreases the risk of aspiration because air is flowing out rather than into the lungs. In adults, the timing of swallows during expiration appears to depend upon posture. In a study conducted in adults, swallows occurred predominantly during late expiration when feeding was in the upright position and in early expiration when subjects were on their hands and knees [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether posture affects the timing of swallowing in infants is not known. One study observed that preterm infants (&lt;30 weeks gestation), fed in the customary semi-reclined position, swallowed primarily during inspiration and deglutition apnea (when they do not breathe), whereas full term infants swallow more frequently at the end of inspiration and end of expiration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/55\">",
"     55",
"    </a>",
"    ]. This may explain the higher frequency of aspiration observed in preterm compared to full term infants.",
"   </p>",
"   <p>",
"    Infants have additional mechanisms to protect the airway. As an example, when the milk flow is too fast, an infant can stop the milk flow by occluding the nipple hole with the tongue. This allows for catch-up breathing when needed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/48\">",
"     48",
"    </a>",
"    ]. Preterm infants breathe customarily between 40 to 60",
"    <span class=\"nowrap\">",
"     breaths/min",
"    </span>",
"    or 1 to 1.5",
"    <span class=\"nowrap\">",
"     cycle/sec.",
"    </span>",
"    The duration of a swallow can vary between 0.35 and 0.7 sec. Because air flow is interrupted during a swallow, an increase in the frequency of swallowing or breathing may result in decreased gas exchange as respiration is hampered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Swallowing and sucking occur as early as 12 and 15 weeks gestation, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/12\">",
"     12",
"    </a>",
"    ]. Infants born at term are able to coordinate sucking, swallowing, and breathing. Whether development of this coordination is accelerated after preterm birth is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INFANT'S BEHAVIORAL STATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infant's behavioral state affects oral feeding performance. Quiet and alert behavior is optimal for feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/25\">",
"     25",
"    </a>",
"    ]. Sucking, swallowing, and breathing are more likely to be coordinated in that state. Quiet and alert behavior is less sustained in preterm infants, who change states frequently. Feeding performance improves as the frequency of state transitions decreases with maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INFANT'S ORGANIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infant's organization will also affect his or her oral feeding performance. Although infants cannot speak, they do communicate through their behavioral state and organization. As such, it is important to watch them while they feed, as they will communicate to their caregivers whether they are ready to feed, can continue, or need to stop feeding. Such attentive approach can only enhance their safety and oral feeding performance.",
"   </p>",
"   <p>",
"    The best time for an infant to focus on feeding by mouth is when",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    is in an organized state. Trying to orally feed an infant who exhibits disorganized behavior is difficult and may put the infant at risk of aspiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oxygen desaturation. Often a pacifier is calming, and may help infants reorganize themselves and improve oral feeding.",
"   </p>",
"   <p>",
"    Signs of organized infant behavior include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relaxation",
"     </li>",
"     <li>",
"      Comfortable breathing",
"     </li>",
"     <li>",
"      Arms folded towards the body",
"     </li>",
"     <li>",
"      Hands near chest",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, signs of disorganization include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hands open and turned outward",
"     </li>",
"     <li>",
"      Outstretched arms",
"     </li>",
"     <li>",
"      Facial grimace",
"     </li>",
"     <li>",
"      Strained breathing",
"     </li>",
"     <li>",
"      Tongue sticking out",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FEEDING DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral feeding problems ought to be addressed as soon as possible in order to minimize potential long-term feeding aversion and caregivers' stress. Feeding difficulties affect as many as 25 percent of children at some time, with varying degrees of severe and prolonged complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/12\">",
"     12",
"    </a>",
"    ]. Disorders can include anatomic, medical, or behavior problems, or result from developmental immaturity. These problems often interfere with the coordination of sucking, swallowing, and breathing.",
"   </p>",
"   <p>",
"    Children with anatomic malformations (eg, cleft lip and palate) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/58\">",
"     58",
"    </a>",
"    ] or chronic disorders (eg, cerebral palsy) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/57\">",
"     57",
"    </a>",
"    ] are more likely to be affected. Neurologic dysphagia may result from compression of the brainstem and cranial nerves IX-XII [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Feeding is closely associated with learned social interaction, and is important for the development of normal eating behavior. This behavior is influenced by the child's mental capabilities and communication skills, as well as the parent's attitude toward the child. As a result, feeding disorders can lead to failure to thrive and interfere with the child's social, mental, and physical capabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Feeding disorder team",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with feeding disorders benefit from a multidisciplinary approach, which may include the following team members [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nutritionist to perform a dietary evaluation and make adjustments in feeding",
"     </li>",
"     <li>",
"      Occupational and speech therapists for assessment of oromotor and swallowing function",
"     </li>",
"     <li>",
"      Psychologist to evaluate maternal and infant behavior and mother-infant interaction",
"     </li>",
"     <li>",
"      Pediatric gastroenterologist to identify gastrointestinal disorders, if any",
"     </li>",
"     <li>",
"      Lactation consultant for breastfeeding issues",
"     </li>",
"     <li>",
"      Additional subspecialists as needed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A nurse can coordinate care among team members and serve as the primary contact for the family and referring physician. In general, correction of a feeding disorder requires weeks to months. Regular follow-up is needed to assess progress and compliance with treatment and to revise the treatment plan as needed. Education of the family is an important component of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Difficulties in feeding may result from inexperience of the caretaker",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infant. They usually are corrected with teaching by an experienced nurse, lactation consultant, or feeding therapist. Severe feeding disorders, such as those that impede growth or delay hospital discharge, require evaluation to identify a cause.",
"   </p>",
"   <p>",
"    Depending upon the abnormality, specific interventions may be helpful. These interventions also may facilitate the transition from tube to oral feedings in preterm infants. Some commonly used approaches are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sucking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with an immature sucking pattern may have difficulty with feeding when the milk flow is too rapid. It often occurs when preterm infants transition from gavage to oral feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/5,13\">",
"     5,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One method to retard flow is to thicken the milk. An alternative approach is to use a bottle that allows self-paced flow and prevents the vacuum build-up that occurs during feeding. This type of bottle eliminates the hydrostatic pressure so that milk flows only when the infant is feeding. Elimination of the vacuum build-up facilitates milk transfer for infants with weak suction. In a study of preterm infants less than 30 weeks gestational age, the rate of milk transfer was greater, and feedings were more likely to be completed within the specified time period with a self-paced vacuum-free compared to standard bottles [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/60\">",
"     60",
"    </a>",
"    ]. Such improvement was associated with infants' ability to use a more mature suck [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interventions often are used to strengthen a weak or disorganized suck, although their efficacy is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/12\">",
"     12",
"    </a>",
"    ]. As an example, a combination of cheek and chin support is commonly used by feeding therapists to facilitate stronger sucking by reducing excessive jaw movement and improving cheek support and lip seal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/3\">",
"     3",
"    </a>",
"    ]. However, any improvement cannot rule out the effect of maturation alone.",
"   </p>",
"   <p>",
"    Studies using a variety of interventions (eg,",
"    <span class=\"nowrap\">",
"     tactile/kinesthetic",
"    </span>",
"    stimulation, massage therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/62\">",
"     62",
"    </a>",
"    ], and nonnutritive oral exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]) have shown benefits, such as accelerating attainment of independent oral feeding, improving growth and behavioral state organization, enhancing sucking skills, and decreasing length of hospitalization. However, to gain broader acceptance, confirmation of benefits from some of these interventions is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Swallowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A videofluoroscopic swallowing study (modified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow) can identify swallowing disorders in infants with feeding difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/30\">",
"     30",
"    </a>",
"    ]. This study may be conducted in conjunction with an upper gastrointestinal series to exclude anatomic abnormalities. In some centers, fiberoptic endoscopy is used for further evaluation of dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No evidence-based interventions specifically aimed at improving swallowing during oral feeding have been fully described. Recently, a swallow exercise provided prior to the introduction of oral feeding has been shown to enhance attainment of independent oral feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Suck-swallow-breathe coordination",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific intervention has yet been developed to improve coordination of sucking and swallowing with breathing. A general approach is to optimize the infant's state, posture, tone, and behavioral organization. External pacing may be helpful. In this method, the bottle is removed after several sucks and swallows to allow time for the infant to breathe.",
"   </p>",
"   <p>",
"    Thickening the milk and using a self-paced flow bottle may enhance synchronization by reducing flow. However, thickened milk may hamper flow through the nipple hole depending on the diameter of the holes. When this occurs, caregivers routinely enlarge the opening without regard to the flow rate engendered. This, in turn, may put the infant at risk of aspiration due to too rapid of a flow. Thus, the decision to enlarge a nipple hole should not be readily made without thinking about its potential harmful effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems with sucking, swallowing, and coordination with breathing may interfere with successful breastfeeding. Specific interventions depend upon the cause. The following are examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arousal techniques in preterm infants may help maintain a state of arousal adequate for oral feeding.",
"     </li>",
"     <li>",
"      Positioning techniques, such as the football hold, provide more cheek and jaw support than does the traditional cradle hold and may help infants obtain a better latch on and remain on the breast.",
"     </li>",
"     <li>",
"      A thin silicone nipple shield may help infants who have difficulty remaining on the breast [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21576/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more complete discussion on breastfeeding the preterm infant is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13657?source=see_link\">",
"     \"Breast milk expression for the preterm infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691788512\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safe and successful oral feeding for the newborn infant depends upon the proper development of sucking, swallowing, and breathing, and their coordination in order to minimize oxygen desaturation, apnea, bradycardia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspiration, and enhance feeding efficiency. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Suck-swallow-breath coordination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sucking requires appropriate integration and timing of movements of the lips, cheeks, tongue, and palate in order to draw milk into the mouth, form a bolus, and propel it to the back of the pharynx to initiate the swallowing reflex. The activity of the oropharyngeal muscles must be coordinated to protect the airway and the nasal passages as the bolus travels to the esophagus. Sucking is dependent upon postmenstrual age (PMA), and it is uncertain at what PMA can preterm infants successfully suck. Two types of sucking are recognized: nutritive and nonnutritive. Nutritive sucking occurs during feeding, while nonnutritive sucking occurs without transfer of milk. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sucking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Swallowing requires the proper coordination of movement of oropharyngeal structures, including the tongue, soft palate, pharynx, larynx, and esophagus. Proper swallowing is also dependent upon PMA. In very premature infants, immaturity results in poor bolus formation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lack of synchrony in the initiation of the swallowing reflex, laryngeal closure,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      esophageal opening. These can lead to aspiration of milk before, during, or after a swallow. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Swallowing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Feeding performance can be affected by an infant&rsquo;s behavioral state and organization. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Infant's behavioral state'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Infant's organization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Feeding disorders are due to anatomic, medical, or behavior problems, or result from developmental immaturity, which often interfere with the coordination of sucking, swallowing, and breathing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Feeding disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with feeding disorders often benefit from a multidisciplinary approach, which may include a nutritionist, occupational and speech therapists, psychologists, lactation consultant, and a pediatric gastroenterologist. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Feeding disorder team'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Difficulties in feeding may result from inexperience of the caretaker",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      infant. They usually are corrected with teaching by an experienced nurse, lactation consultant, or feeding therapist. Severe feeding disorders, such as those that impede growth or delay hospital discharge, require further evaluation to identify a specific cause. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/1\">",
"      ARDRAN GM, KEMP FH, LIND J. A cineradiographic study of bottle feeding. Br J Radiol 1958; 31:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/2\">",
"      ARDRAN GM, KEMP FH, LIND J. A Cineradiographic study of breast feeding. Br J Radiol 1958; 31:156.",
"     </a>",
"    </li>",
"    <li>",
"     Wolf, LS, Glass, RP. Feeding and swallowing disorders in infancy: Assessment and management. Therapy Skill Builders, Tucson, AZ 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/4\">",
"      Lau C, Schanler RJ. Oral motor function in the neonate. Clin Perinatol 1996; 23:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/5\">",
"      Lau C, Sheena HR, Shulman RJ, Schanler RJ. Oral feeding in low birth weight infants. J Pediatr 1997; 130:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/6\">",
"      Sameroff AJ. The components of sucking in the human newborn. J Exp Child Psychol 1968; 6:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/7\">",
"      Waterland RA, Berkowitz RI, Stunkard AJ, Stallings VA. Calibrated-orifice nipples for measurement of infant nutritive sucking. J Pediatr 1998; 132:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/8\">",
"      Tamura Y, Horikawa Y, Yoshida S. Co-ordination of tongue movements and peri-oral muscle activities during nutritive sucking. Dev Med Child Neurol 1996; 38:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/9\">",
"      Miller JL, Kang SM. Preliminary ultrasound observation of lingual movement patterns during nutritive versus non-nutritive sucking in a premature infant. Dysphagia 2007; 22:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/10\">",
"      Wolff PH. The serial organization of sucking in the young infant. Pediatrics 1968; 42:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/11\">",
"      Wrotniak BH, Stettler N, Medoff-Cooper B. The relationship between birth weight and feeding maturation in preterm infants. Acta Paediatr 2009; 98:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/12\">",
"      Lau C, Hurst N. Oral feeding in infants. Curr Probl Pediatr 1999; 29:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/13\">",
"      Lau C, Alagugurusamy R, Schanler RJ, et al. Characterization of the developmental stages of sucking in preterm infants during bottle feeding. Acta Paediatr 2000; 89:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/14\">",
"      Amaizu N, Shulman R, Schanler R, Lau C. Maturation of oral feeding skills in preterm infants. Acta Paediatr 2008; 97:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/15\">",
"      Lau C, Smith EO. A novel approach to assess oral feeding skills of preterm infants. Neonatology 2011; 100:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/16\">",
"      Lau C, Kusnierczyk I. Quantitative evaluation of infant's nonnutritive and nutritive sucking. Dysphagia 2001; 16:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/17\">",
"      DiPietro JA, Cusson RM, Caughy MO, Fox NA. Behavioral and physiologic effects of nonnutritive sucking during gavage feeding in preterm infants. Pediatr Res 1994; 36:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/18\">",
"      Pickler RH, Higgins KE, Crummette BD. The effect of nonnutritive sucking on bottle-feeding stress in preterm infants. J Obstet Gynecol Neonatal Nurs 1993; 22:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/19\">",
"      Field, T. Sucking for stress reduction, growth and development during infancy. Pediatr Basics 1993; 64:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/20\">",
"      Bernbaum JC, Pereira GR, Watkins JB, Peckham GJ. Nonnutritive sucking during gavage feeding enhances growth and maturation in premature infants. Pediatrics 1983; 71:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/21\">",
"      Widstr&ouml;m AM, Marchini G, Matthiesen AS, et al. Nonnutritive sucking in tube-fed preterm infants: effects on gastric motility and gastric contents of somatostatin. J Pediatr Gastroenterol Nutr 1988; 7:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/22\">",
"      De Curtis M, McIntosh N, Ventura V, Brooke O. Effect of nonnutritive sucking on nutrient retention in preterm infants. J Pediatr 1986; 109:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/23\">",
"      Ernst JA, Rickard KA, Neal PR, et al. Lack of improved growth outcome related to nonnutritive sucking in very low birth weight premature infants fed a controlled nutrient intake: a randomized prospective study. Pediatrics 1989; 83:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/24\">",
"      Kanarek KS, Shulman D. Non-nutritive sucking does not increase blood levels of gastrin, motilin, insulin and insulin-like growth factor 1 in premature infants receiving enteral feedings. Acta Paediatr 1992; 81:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/25\">",
"      Als, H. A synactive model of neonatal behavior organization: framework for the assessment of neurobehavioral development in the preterm infant and for support of infants and parents in the neonatal intensive care environment. Phys Occup Ther Pediatr 1986; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/26\">",
"      Bingham PM, Ashikaga T, Abbasi S. Prospective study of non-nutritive sucking and feeding skills in premature infants. Arch Dis Child Fetal Neonatal Ed 2010; 95:F194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/27\">",
"      Lau, C. Oral feeding in the preterm infant. NeoRev 2006; 7:e19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/28\">",
"      Barlow SM, Finan DS, Lee J, Chu S. Synthetic orocutaneous stimulation entrains preterm infants with feeding difficulties to suck. J Perinatol 2008; 28:541.",
"     </a>",
"    </li>",
"    <li>",
"     Logemann, JA. Evaluation and treatment of swallowing disorders. 2nd ed. Pro-Ed Publication, Austin, 1998.",
"    </li>",
"    <li>",
"     Arvedson, JC, Lefton-Greif, MA. Pediatric videofluoroscopic swallow studies. A profession manual with caregiver guidelines. Communication Skill Builders, San Antonio 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/31\">",
"      Buchholz DW, Bosma JF, Donner MW. Adaptation, compensation, and decompensation of the pharyngeal swallow. Gastrointest Radiol 1985; 10:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/32\">",
"      Miller AJ. Deglutition. Physiol Rev 1982; 62:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/33\">",
"      Diamant NE. Firing up the swallowing mechanism. Nat Med 1996; 2:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/34\">",
"      Barlow SM, Estep M. Central pattern generation and the motor infrastructure for suck, respiration, and speech. J Commun Disord 2006; 39:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/35\">",
"      Hamdy S, Aziz Q, Rothwell JC, et al. The cortical topography of human swallowing musculature in health and disease. Nat Med 1996; 2:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/36\">",
"      Hamdy S, Mikulis DJ, Crawley A, et al. Cortical activation during human volitional swallowing: an event-related fMRI study. Am J Physiol 1999; 277:G219.",
"     </a>",
"    </li>",
"    <li>",
"     Peiper, A. Cerebral function in infancy and childhood. Consultants Bureau, New York 1963. p.444.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/38\">",
"      Omari T. Lower esophageal sphincter function in the neonate. NeoReviews 2006; 7:e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/39\">",
"      Jadcherla SR, Esophageal motility in the human neonate. NeoReviews 2006; 2:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/40\">",
"      Richter JE, Wu WC, Johns DN, et al. Esophageal manometry in 95 healthy adult volunteers. Variability of pressures with age and frequency of \"abnormal\" contractions. Dig Dis Sci 1987; 32:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/41\">",
"      Omari TI, Miki K, Fraser R, et al. Esophageal body and lower esophageal sphincter function in healthy premature infants. Gastroenterology 1995; 109:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/42\">",
"      Jadcherla SR, Duong HQ, Hoffmann RG, Shaker R. Esophageal body and upper esophageal sphincter motor responses to esophageal provocation during maturation in preterm newborns. J Pediatr 2003; 143:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/43\">",
"      Jadcherla SR, Stoner E, Gupta A, et al. Evaluation and management of neonatal dysphagia: impact of pharyngoesophageal motility studies and multidisciplinary feeding strategy. J Pediatr Gastroenterol Nutr 2009; 48:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/44\">",
"      Jadcherla SR, Gupta A, Stoner E, et al. Neuromotor markers of esophageal motility in feeding intolerant infants with gastroschisis. J Pediatr Gastroenterol Nutr 2008; 47:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/45\">",
"      Gupta A, Gulati P, Kim W, et al. Effect of postnatal maturation on the mechanisms of esophageal propulsion in preterm human neonates: primary and secondary peristalsis. Am J Gastroenterol 2009; 104:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/46\">",
"      Jadcherla SR, Gupta A, Stoner E, et al. Pharyngeal swallowing: defining pharyngeal and upper esophageal sphincter relationships in human neonates. J Pediatr 2007; 151:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/47\">",
"      Koenig JS, Davies AM, Thach BT. Coordination of breathing, sucking, and swallowing during bottle feedings in human infants. J Appl Physiol 1990; 69:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/48\">",
"      Bu'Lock F, Woolridge MW, Baum JD. Development of co-ordination of sucking, swallowing and breathing: ultrasound study of term and preterm infants. Dev Med Child Neurol 1990; 32:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/49\">",
"      Shivpuri CR, Martin RJ, Carlo WA, Fanaroff AA. Decreased ventilation in preterm infants during oral feeding. J Pediatr 1983; 103:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/50\">",
"      Nishino T, Yonezawa T, Honda Y. Effects of swallowing on the pattern of continuous respiration in human adults. Am Rev Respir Dis 1985; 132:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/51\">",
"      Bamford O, Taciak V, Gewolb IH. The relationship between rhythmic swallowing and breathing during suckle feeding in term neonates. Pediatr Res 1992; 31:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/52\">",
"      McFarland DH, Lund JP. Modification of mastication and respiration during swallowing in the adult human. J Neurophysiol 1995; 74:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/53\">",
"      Shaker CS. Nipple feeding premature infants: a different perspective. Neonatal Netw 1990; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/54\">",
"      McFarland DH, Lund JP, Gagner M. Effects of posture on the coordination of respiration and swallowing. J Neurophysiol 1994; 72:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/55\">",
"      Lau C, Smith EO, Schanler RJ. Coordination of suck-swallow and swallow respiration in preterm infants. Acta Paediatr 2003; 92:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/56\">",
"      Babbitt RL, Hoch TA, Coe DA, et al. Behavioral assessment and treatment of pediatric feeding disorders. J Dev Behav Pediatr 1994; 15:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/57\">",
"      Love RJ, Hagerman EL, Taimi EG. Speech performance, dysphagia and oral reflexes in cerebral palsy. J Speech Hear Disord 1980; 45:59.",
"     </a>",
"    </li>",
"    <li>",
"     Prontnicki, J. Presentation: symptomatology and etiology of dysphagia. In: Rosenthal, SR, Sheppard, JJ, Lotze, M (Eds), Dysphagia and the child with developmental disabilities: Medical, clinical, and family interventions, Singular Pub Group, San Diego, 1995. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/59\">",
"      Toporoff, EG, Story, M. The feeding arena: a developmentally based model for assessing mother-infant feeding interactions. Topics Clin Nutr 1997; 12:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/60\">",
"      Lau C, Schanler RJ. Oral feeding in premature infants: advantage of a self-paced milk flow. Acta Paediatr 2000; 89:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/61\">",
"      Fucile S, Gisel E, Schanler RJ, Lau C. A controlled-flow vacuum-free bottle system enhances preterm infants' nutritive sucking skills. Dysphagia 2009; 24:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/62\">",
"      Field TM, Schanberg SM, Scafidi F, et al. Tactile/kinesthetic stimulation effects on preterm neonates. Pediatrics 1986; 77:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/63\">",
"      Fucile S, Gisel EG, Lau C. Effect of an oral stimulation program on sucking skill maturation of preterm infants. Dev Med Child Neurol 2005; 47:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/64\">",
"      Gaebler CP, Hanzlik JR. The effects of a prefeeding stimulation program on preterm infants. Am J Occup Ther 1996; 50:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/65\">",
"      Fucile S, Gisel E, Lau C. Oral stimulation accelerates the transition from tube to oral feeding in preterm infants. J Pediatr 2002; 141:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/66\">",
"      Hartnick CJ, Hartley BE, Miller C, Willging JP. Pediatric fiberoptic endoscopic evaluation of swallowing. Ann Otol Rhinol Laryngol 2000; 109:996.",
"     </a>",
"    </li>",
"    <li>",
"     Lau C, Swallow Intervention Can Enhance Oral Feeding Performance in Preterm Infants. E-PAS 2009:5508 158 2009;.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21576/abstract/68\">",
"      Meier PP, Brown LP, Hurst NM, et al. Nipple shields for preterm infants: effect on milk transfer and duration of breastfeeding. J Hum Lact 2000; 16:106.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4976 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.232-9BEAA163C5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21576=[""].join("\n");
var outline_f21_4_21576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H691788512\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUCKING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nutritive sucking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonnutritive sucking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SWALLOWING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUCK-SWALLOW-BREATH COORDINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INFANT'S BEHAVIORAL STATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INFANT'S ORGANIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FEEDING DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Feeding disorder team",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sucking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Swallowing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Suck-swallow-breathe coordination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H691788512\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4976|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/1/17428\" title=\"figure 1\">",
"      Scale evaluate newborn suck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4976|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?22/21/22866\" title=\"waveform 1\">",
"      Recordings suck swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/35/27184\" title=\"waveform 2\">",
"      Nonnutritive nutritive suck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13657?source=related_link\">",
"      Breast milk expression for the preterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27765?source=related_link\">",
"      Discharge planning for high-risk newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=related_link\">",
"      Nutritional composition of human milk and preterm formula for the premature infant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_4_21577="Withdrawal or avoidance of glucocorticoids after renal transplantation";
var content_f21_4_21577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Withdrawal or avoidance of glucocorticoids after renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/4/21577/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21577/contributors\">",
"     Brent W Miller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21577/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/4/21577/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21577/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/4/21577/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/4/21577/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/4/21577/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of glucocorticoids (also called corticosteroids or steroids) in transplantation was first discovered in the 1950s with experiments demonstrating the ability of these agents to enhance survival of rabbit skin grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/1\">",
"     1",
"    </a>",
"    ]. These observations led to the clinical use of glucocorticoids to reverse severe renal transplant rejection.",
"   </p>",
"   <p>",
"    The combined administration of glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    was subsequently introduced as maintenance immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/2\">",
"     2",
"    </a>",
"    ]. Significant benefits with this regimen helped transform transplantation from an experimental, infrequently used procedure to a widespread, extremely successful clinical option.",
"   </p>",
"   <p>",
"    Most transplant centers currently administer large doses of glucocorticoids perioperatively and immediately postoperatively. This usually consists of a \"pulse\" intraoperative dose of 5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , which is followed by 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . This is subsequently tapered to approximately 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of prednisone by one year or less. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the immunosuppressive benefits derived from this glucocorticoid regimen are counterbalanced by the possible induction of numerous major adverse effects (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    ). These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cortical bone mass quickly declines, possibly leading to osteopenia, skeletal fractures, and avascular necrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"       \"Parathyroid and mineral metabolism after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Established diabetes is worsened, while de novo cases of diabetes may develop. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=see_link\">",
"       \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wound healing is a significant problem, particularly among the obese.",
"     </li>",
"     <li>",
"      There are alterations in lipid metabolism, possibly resulting in an atherogenic milieu. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link\">",
"       \"Lipid abnormalities after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other significant adverse effects include an enhanced risk of cataract formation, hypertension, and obesity.",
"   </p>",
"   <p>",
"    To minimize toxicity and decrease overall immunosuppression, tapering and ultimate withdrawal of glucocorticoids has been attempted. Cessation of glucocorticoid therapy is often associated with a fall in blood pressure and in diabetic patients, better glycemic control; total cholesterol levels also fall, but there is an equivalent reduction in HDL-cholesterol and therefore, an uncertain effect on cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/3\">",
"     3",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    ). Prevention of osteopenia and aseptic necrosis of bone are other potential benefits; there are, however, limited data at present to confirm these results.",
"   </p>",
"   <p>",
"    Minimizing glucocorticoid use in the setting of organ transplantation has therefore been a goal for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In the United States in 2004, glucocorticoid avoidance regimens were administered to 23 percent of all first kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/7\">",
"     7",
"    </a>",
"    ]. Among those discharged on glucocorticoids (approximately 77 percent), approximately 10 percent had glucocorticoids completely withdrawn by one year post-transplant. Further, in 2007, approximately 30 percent of kidney transplant recipients were discharged on an immunosuppressive regimen that did not include corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, although glucocorticoids are currently administered to the majority of kidney transplant recipients, strategies aimed at minimizing or avoiding these agents are increasingly used.",
"   </p>",
"   <p>",
"    A review of glucocorticoid withdrawal or avoidance in the renal transplant patient with stable renal function is presented here. Withdrawal of immunosuppression in the patient with a failed renal allograft is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41111?source=see_link\">",
"     \"Withdrawal of immunosuppression after renal transplant failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MINIMIZING GLUCOCORTICOID USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with conventional immunosuppressive regimens, exposure to glucocorticoids can be further minimized via several different strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower doses administered earlier after transplantation",
"     </li>",
"     <li>",
"      Complete withdrawal, which can either be performed early after transplantation (approximately three to six months post-surgery) or at a later time (after one year)",
"     </li>",
"     <li>",
"      Complete avoidance, which most frequently has been utilized with a calcineurin inhibitor-based immunosuppressive regimen and polyclonal antibody induction therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effectiveness of such strategies is dependent in part upon the ability of the remaining non-glucocorticoid immunosuppressive agents to suppress the anti-allograft immune response. The continuing introduction of more selective and possibly improved immunosuppressive agents (compared to traditional drugs), such as targeted-antibody preparations, may eventually permit a completely glucocorticoid-free maintenance regimen.",
"   </p>",
"   <p>",
"    An increasingly large number of registry studies and meta-analyses have been published concerning the outcomes associated with minimizing glucocorticoid use [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. In general, the risk of acute rejection is markedly increased with the withdrawal of corticosteroids weeks to months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/15\">",
"     15",
"    </a>",
"    ]. However, some claim that overall benefits may be found in certain patients if corticosteroids are discontinued during the first week after transplantation. As an example, the 2009 KDIGO clinical practice guidelines suggest that corticosteroids may be discontinued during the first week after transplantation in patients who are at low-immunologic risk and who also receive induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not agree with the KDIGO guidelines. Overall, we consider that the current published evidence suggests that low-dose corticosteroid therapy should be continued indefinitely at low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    of 5 mg per day. Many of the trials that have shown benefit with glucocorticoid avoidance or are currently ongoing have evaluated short-term outcomes in patients at relatively low risk of adverse outcomes. Many of these avoidance trials are also enrolling a low number of African-Americans, a group at particularly high risk of rejection. Outcomes are significantly affected by these strategies, a subject that is discussed in the relevant sections elsewhere within this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Very low dose maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, most centers attempt to taper glucocorticoids to approximately 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or even less) by one year or sooner. In the absence of acute rejection, for example, we generally reduce glucocorticoids to a dose of 5 mg per day by one month following kidney transplantation. Overall, the benefit of maintenance low-dose glucocorticoids at the doses currently utilized may include improved immunosuppression, modulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    nephrotoxicity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ability to avoid cyclosporine use.",
"   </p>",
"   <p>",
"    Such doses are associated with decreased rejection and avoidance of chronic kidney allograft nephropathy compared with early steroid",
"    <span class=\"nowrap\">",
"     withdrawal/avoidance.",
"    </span>",
"    This was best shown in the only prospective, well-designed study that compared very early steroid cessation to low-dose long-term steroid therapy in kidney recipients receiving modern maintenance immunosuppression. In this trial, 386 patients were randomly assigned to corticosteroid withdrawal at one week post-transplant (CSWD) or continuance of corticosteroids (CCS) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients received antibody induction therapy with either rabbit anti-thymocyte globulin (68 percent) or intereukin-2 receptor antibody (32 percent). Maintenance therapy consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and seven days of corticosteroids followed by blinded randomization to either the CSWD group or a CCS group that was tapered to 5 milligrams of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    daily by six months after transplant.",
"   </p>",
"   <p>",
"    At follow-up at five years, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the primary composite endpoint (death, allograft loss, or",
"      <span class=\"nowrap\">",
"       moderate/severe",
"      </span>",
"      rejection) or in any of the individual components.",
"     </li>",
"     <li>",
"      The very early withdrawal group was associated with significant increases in the incidence of chronic allograft nephropathy (10 versus 4 percent) as well as biopsy-proven acute rejection (18 versus 11 percent). Given that the rate of",
"      <span class=\"nowrap\">",
"       moderate/severe",
"      </span>",
"      rejection was similar in the two groups, these findings suggest that very early withdrawal increased the risk of mild rejection.",
"     </li>",
"     <li>",
"      Use of rabbit anti-thymocyte globulin was associated with an increased incidence of rejection only among those who received induction with an interleukin-2 receptor antibody.",
"     </li>",
"     <li>",
"      In terms of corticosteroid-associated side effects, there were no significant differences in blood pressure, new-onset diabetes, serum cholesterol or low-density lipoprotein levels, and rates of bone fracture or cataracts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the authors concluded that very early withdrawal is safe and provides similar five-year renal allograft outcomes, this strategy resulted in double the rate of chronic allograft nephropathy compared with continuance of corticosteroid therapy. These findings suggest that continued maintenance therapy is preferred to very early withdrawal.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Withdrawal several weeks to months after surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of glucocorticoid withdrawal within several weeks to months after surgery were quickly realized to be accompanied by a significantly increased risk of acute rejection and possible decreased long-term allograft survival. This is particularly true if withdrawal is performed less than three to six months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, early cessation of glucocorticoids is associated with an increased incidence of acute rejection and a possible decrease in long-term (more than two years) graft survival. As a result, early glucocorticoid withdrawal or avoidance has been abandoned by most transplant centers for the majority of patients. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The adverse effects of early withdrawal upon allograft survival appear to emerge only after an extended period of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ]. In some studies, such immunosuppressive strategies did not affect early (less than two years) allograft survival. By comparison, significantly decreased long-term survival was reported in a multicenter Canadian trial, which evaluated the outcome of 523 stable transplant recipients who were randomly assigned at day 90 following renal transplant to placebo or alternate-day",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/21\">",
"     21",
"    </a>",
"    ]. Adverse allograft survival results associated with total glucocorticoid withdrawal were not evident until follow-up at",
"    <strong>",
"     five",
"    </strong>",
"    years (73 and 85 percent for the placebo and prednisone groups, respectively).",
"   </p>",
"   <p>",
"    The success with glucocorticoid withdrawal may depend in part upon the effectiveness of the remaining agents that constitute the immunosuppressive regimen. Studies evaluating glucocorticoid withdrawal in patients treated with calcineurin inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) have largely shown worse outcomes, except in patients receiving induction therapy or in patients at low to standard risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/20,22-27\">",
"     20,22-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Withdrawal years after transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of studies evaluating withdrawal at later time points are conflicting, demonstrating the need for caution concerning any glucocorticoid withdrawal regimen. We believe that there is little long-term benefit and a small, but clear",
"    <strong>",
"     risk",
"    </strong>",
"    observed in patients withdrawn from small doses of glucocorticoids after one year. Patients chosen for glucocorticoid withdrawal at our center have a low-risk profile and an identifiable potential benefit for withdrawal. Thus, we have withdrawn glucocorticoids after one year in less than 1 percent of renal transplant patients at our center.",
"   </p>",
"   <p>",
"    The following is an overview of some of the studies that have examined this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/10,28-35\">",
"     10,28-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis published in 2000 of 20 glucocorticoid withdrawal studies reported that withdrawal was also associated with a",
"      <strong>",
"       higher",
"      </strong>",
"      relative risk of graft failure (relative risk = 1.34) and an",
"      <strong>",
"       increased",
"      </strong>",
"      risk of acute rejection (14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/10\">",
"       10",
"      </a>",
"      ]. These adverse results were worse than those from studies evaluating the outcomes of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      withdrawal.",
"     </li>",
"     <li>",
"      A large prospective but nonrandomized European study reported that glucocorticoid withdrawal may result in improved graft and patient survival versus that observed with matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/31\">",
"       31",
"      </a>",
"      ]. In this multicenter study, 1110 cadaveric kidney recipients underwent slow glucocorticoid withdrawal after at least six months post-transplantation. Matched controls selected from the database by the investigators were derived from the Collaborative Transplant study database. Both groups were similar, including a low-risk for rejection, except that the controls had lower serum creatinine concentrations (less than 1.47",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [130",
"      <span class=\"nowrap\">",
"       &micro;mol/L]",
"      </span>",
"      versus less than 2.94",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [260",
"      <span class=\"nowrap\">",
"       &micro;mol/L])",
"      </span>",
"      for the withdrawal patients.",
"      <br/>",
"      <br/>",
"      At seven years, superior benefits with withdrawal were noted for graft survival (92 versus 75 percent), patient survival (89 versus 84 percent), and death-censored graft survival (82 versus 88 percent). There were no differences in rates of acute rejection and allograft dysfunction.",
"      <br/>",
"      <br/>",
"      Although intriguing because of demonstrable clinical benefit (better bone density in the withdrawal group), significant limitations of this study include the lack of randomization, heterogeneous immunosuppressive regimens, and loose guidelines for timing and duration of glucocorticoid withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/36\">",
"       36",
"      </a>",
"      ]. Further, at any point in time during the study, approximately 30 to 40 percent of patients were treated with glucocorticoids, suggesting an adverse clinical event.",
"     </li>",
"     <li>",
"      Limited data suggest that the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil in those undergoing late withdrawal may not be associated with adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. In one study, 212 patients receiving triple immunosuppressive therapy consisting of mycophenolate mofetil (1000 mg twice daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (trough level of 125 to 175",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (without antibody induction therapy) were randomly assigned at six months post-transplant to prednisone withdrawal, cyclosporine withdrawal, or continued triple therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/33\">",
"       33",
"      </a>",
"      ]. At two years post-transplant, the incidence of biopsy-proven acute and chronic rejection was higher in the prednisone withdrawal than the control group (4 and 1.4 percent for acute and 5 and 1.4 percent for chronic rejection, respectively); by comparison, the cyclosporine withdrawal group had a significantly higher incidence of acute and chronic rejection (22 and 14 percent). At 18 months after cessation of glucocorticoid therapy, the prednisone withdrawal group, compared with controls, had a lower mean blood pressure and similar renal function and patient and graft survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glucocorticoid-free regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although glucocorticoid avoidance is popular, it is unlikely to provide the best overall risk-to-benefit ratio with maintenance immunosuppressive therapy in renal transplantation. Many glucocorticoid avoidance protocols have chosen low-risk individuals and utilized aggressive induction therapy. Currently, we do not recommend glucocorticoid&ndash;free immunosuppressive regimens based on current data.",
"   </p>",
"   <p>",
"    The following is an overview of the data, including a historical perspective, that have examined the efficacy of glucocorticoid-free regimens in kidney transplantation.",
"   </p>",
"   <p>",
"    Glucocorticoid-free immunosuppression was attempted with some success following the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in the 1980s. As an example, a multicenter European study of 232 cadaveric renal transplants demonstrated a one-year allograft survival rate of 77 percent with cyclosporine only as compared to 63 percent in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    control group [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the 1990s, a transplant group in Denmark has also successfully adopted a glucocorticoid-free immunosuppression strategy (including its avoidance in treating rejection), in combination with induction therapy utilizing Thymoglobulin&reg; (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"     rabbit antithymocyte globulin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In a report summarizing their more recent experience, maintenance immunosuppressive therapy consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and MMF in 100 consecutive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/39\">",
"     39",
"    </a>",
"    ]. Rejections, which were treated with antilymphocyte therapy without glucocorticoids, occurred in only 13 percent of patients. Allograft survival was excellent, with one, two, three, and four year graft survivals of 97, 96, 90, and 82 percent, respectively.",
"   </p>",
"   <p>",
"    A similar protocol with glucocorticoid avoidance in 51 low-risk, living-donor recipients utilized Thymoglobulin&reg; induction therapy, MMF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/40\">",
"     40",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    was discontinued on postoperative day six. Ten percent of patients experienced acute rejection with a 98 percent overall allograft survival at one year. Graft function was no different than historic controls.",
"   </p>",
"   <p>",
"    The five-year experience from the same center in 589 relatively low-risk patients (71 percent living donor, with some patients also receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ) demonstrated comparable results with decreased CMV infections, diabetes mellitus, cataracts, avascular necrosis and fractures as compared to historical controls from the late 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ten-year outcomes were reported from the same group [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/42\">",
"     42",
"    </a>",
"    ]. Among 1241 adult primary transplant recipients (791 living donor and 450 deceased donor) who received allografts between 1999 to 2010, the following outcomes were reported for living donor and deceased donor transplants at ten years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient survival was 71 and 62 percent for living donor and deceased donor transplants, respectively.",
"     </li>",
"     <li>",
"      Graft survival was 61 and 51, respectively.",
"     </li>",
"     <li>",
"      Death-censored graft survival was 79 and 80 percent, respectively.",
"     </li>",
"     <li>",
"      Acute rejection rates were 31 and 25 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both patient and graft survival were comparable to national data reported by the Scientific Registry of Transplant Recipients in 2009. The reported overall rate of new onset diabetes was lower in this group of patients than that reported in historical controls. Other side effects of glucocorticoids, including cataracts, avascular necrosis, and cytomegalovirus were lower in certain subgroups.",
"   </p>",
"   <p>",
"    However, as in prior reports that described favorable outcomes with steroid avoidance strategies, the cohort of patients included in this analysis were relatively low risk compared to transplant recipients encountered elsewhere, with a predominance of living donor kidney recipients, non-African Americans, and nonsensitized recipients and compared to historical controls receiving higher steroid doses for sustained periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the one-year acute rejection rate in the deceased donor group (16 versus 11 percent in living donors, p = 0.07) raises the concern that this strategy must be considered carefully in high-risk individuals.",
"   </p>",
"   <p>",
"    Additional immunosuppressive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    , daclizumab, and Thymoglobulin&reg; (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"     rabbit antithymocyte globulin",
"    </a>",
"    ) have been introduced to try to permit glucocorticoid-free immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/41,44-59\">",
"     41,44-59",
"    </a>",
"    ]. The following is a sample of the results of a few of the more recent better designed studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three hundred kidney transplant recipients were randomly assigned to a second day glucocorticoid withdrawal group or glucocorticoid therapy, with common immunosuppression being",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      for induction therapy and calcineurin inhibitor plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      for maintenance therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/55\">",
"       55",
"      </a>",
"      ]. At three years, acute rejection rates, patient and allograft survival, incidence of chronic allograft nephropathy and subclinical rejection, and kidney function were similar in both arms. By comparison, a significantly lower incidence of post-transplant diabetes mellitus was observed in the glucocorticoid withdrawal group (4 versus 21 percent).",
"     </li>",
"     <li>",
"      One single center study reported the graft and patient survival of 349 patients administered a glucocorticoid-free regimen consisting of Thymoglobulin&reg;, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , and a calcineurin inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/48\">",
"       48",
"      </a>",
"      ]. Acute rejection free graft survival at one and three years was 94 and 92 percent, respectively, and patients and allograft survival at three years was 95 and 93 percent, respectively.",
"     </li>",
"     <li>",
"      In another study, 364 patients were randomly assigned to receive either two doses of daclizumab and, for the first three days, or glucocorticoids, which were tapered to zero by 16 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/47\">",
"       47",
"      </a>",
"      ]. All patients received tacrolimus and mycophenolate mofetil, and both groups also received 100 mg intravenous prednisolone for three days. Acute rejection rates were 31 and 23 percent and allograft failure in 2.2 and 2.4 percent, respectively. Bone density measured by dual energy x-ray absorptiometry declined in both groups at three months, but improved at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term experience with glucocorticoid-free immunosuppression in patients is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/16,61\">",
"     16,61",
"    </a>",
"    ]. In the only prospective, well-designed study comparing very early steroid cessation to low-dose long-term steroid therapy in kidney recipients receiving modern maintenance immunosuppression, 386 patients were randomly assigned to corticosteroid withdrawal at one week post-transplant (CSWD) or continuance of corticosteroids (CCS) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients received antibody induction therapy with either rabbit anti-thymocyte globulin (68 percent) or intereukin-2 receptor antibody (32 percent). Maintenance therapy consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and seven days of corticosteroids followed by blinded randomization to either the CSWD group or a CCS group that was tapered to 5 milligrams of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    daily by six months after transplant.",
"   </p>",
"   <p>",
"    At follow-up at five years, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the primary composite endpoint (death, allograft loss, or",
"      <span class=\"nowrap\">",
"       moderate/severe",
"      </span>",
"      rejection) or in any of the individual components.",
"     </li>",
"     <li>",
"      The very early withdrawal group was associated with significant increases in the incidence of chronic allograft nephropathy (10 versus 4 percent) as well as biopsy-proven acute rejection (18 versus 11 percent). Given that the rate of",
"      <span class=\"nowrap\">",
"       moderate/severe",
"      </span>",
"      rejection was similar in the two groups, these findings suggest that very early withdrawal increased the risk of mild rejection.",
"     </li>",
"     <li>",
"      In terms of corticosteroid-associated side effects, there were no significant differences in blood pressure, new-onset diabetes, serum cholesterol or low-density lipoprotein levels, and rates of bone fracture or cataracts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the authors concluded that very early withdrawal is safe and provides similar five-year renal allograft outcomes, this strategy resulted in double the rate of chronic allograft nephropathy compared with continuance of corticosteroid therapy.",
"   </p>",
"   <p>",
"    A single center four year study found that allograft and patient survival were similar among those with glomerulonephritis treated without glucocorticoids, patients without glomerulonephritis treated without glucocorticoids, and recipients with glomerulonephritis treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the previously cited trials evaluated outcomes in patients at relatively low risk of adverse outcomes. Some trials have also assessed whether glucocorticoid-free regimens are feasible in patients at increased risk, including African-Americans and presensitized patients. As examples [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/22,52,62-64\">",
"     22,52,62-64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of rapid",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      discontinuation among 79 patients at high risk (such as African-Americans or presensitized recipients), three year allograft survival was approximately 95 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study of 206 kidney recipients (including 103 African-Americans) with a maintenance regimen of calcineurin inhibitor plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      found that one year patient and allograft survival was 96 and 88 percent for African-Americans, and 97 and 89 percent for non-African-Americans, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/63\">",
"       63",
"      </a>",
"      ]. However, an increased acute rejection rate was observed in African-Americans (16 versus 13 percent). At five years, allograft and patient survival remained the same for both groups [",
"      <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/64\">",
"       64",
"      </a>",
"      ]. The results from this single-center require verification from either registry or other large single-center analyses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A related issue is the use of maintenance corticosteroids in patients on steroid avoidance regimens who are treated with steroids for an acute rejection episode. One retrospective single center study found that allograft survival was not affected by whether the patient continued to receive steroids, while maintenance steroids lowered the risk of a second acute rejection episode [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/65\">",
"     65",
"    </a>",
"    ]. Further study is required to understand the role of maintenance steroids in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39853556\">",
"    <span class=\"h3\">",
"     Choice of immunosuppressive agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal glucocorticoid-free regimen is not known. A prospective observational study of 82 consecutive transplant recipients found better overall graft survival associated with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"      tacrolimus",
"     </a>",
"     /MMF",
"    </span>",
"    compared with",
"    <span class=\"nowrap\">",
"     tacrolimus/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"      sirolimus",
"     </a>",
"    </span>",
"    at 8.5 years (91 versus 70 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/66\">",
"     66",
"    </a>",
"    ]. By three months after transplantation, estimated GFR was lower in the",
"    <span class=\"nowrap\">",
"     tacrolimus/sirolimus",
"    </span>",
"    group (48 versus 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2). One prospective randomized trial has shown that tacrolimus plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil is also better tolerated compared with sirolimus plus mycophenolate mofetil (MMF) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/67\">",
"     67",
"    </a>",
"    ]. In this study, 122 kidney transplant recipients who received tacrolimus and MMF with rapid glucocorticoid withdrawal for the first months after transplant were assigned to receive MMF, given with either sirolimus or tacrolimus. More patients in the sirolimus group withdrew during the two-year period of the study compared with tacrolimus (63 versus 18 percent). Reasons for withdrawal were related to rejection or medication side effects. The high withdrawal rate may have been due to the absence of glucocorticoids, which may modulate some of the side effects of the sirolimus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9604890\">",
"    <span class=\"h2\">",
"     Recurrent glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroid avoidance is associated with increased risks of recurrent glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/68\">",
"     68",
"    </a>",
"    ]. In one large retrospective study, rapid steroid withdrawal was associated with a higher risk of recurrent glomerulonephritis compared to continued steroids (hazard ratio 4.86, 95% CI 2.34-10.07). This study showed no difference between groups in patient, graft or death-censored graft survival, suggesting no benefit and possible harm from steroid avoidance in patients with a history of glomerulonephritis. In a registry study of 1521 renal transplant recipients in the Australia and New Zealand Dialysis and Transplant Registry, continued glucocorticoid use was strongly related to a reduced risk of IgA recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid withdrawal following renal transplantation remains a controversial issue. Several centers routinely discontinue glucocorticoids, while others continue maintenance glucocorticoids indefinitely [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. The use of polyclonal antibody induction therapy appears to facilitate glucocorticoid withdrawal.",
"   </p>",
"   <p>",
"    Our policy is to individualize therapy based upon a careful assessment of the risk-benefit ratio. In general, our opinion is that, in most patients, long-term calcineurin inhibitor toxicity outweighs the long-term toxicity of low-dose glucocorticoids. We therefore administer low-dose glucocorticoid therapy indefinitely as part of the maintenance immunosuppressive regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Glucocorticoid minimization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of acute rejection, there is little utility in maintaining patients on large doses of glucocorticoids or in tapering glucocorticoids over prolonged periods of time. We therefore reduce the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose to 20 mg daily on postoperative day five with tapering to 5 mg daily by two months following transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Withdrawal several months after surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, we do not recommend early withdrawal (less than six months following transplantation) in the majority of patients. This is because the benefits of withdrawal have not been consistently reproduced and there is a clear risk of acute rejection and decreased renal function. The long-term effect of glucocorticoid withdrawal is unknown.",
"   </p>",
"   <p>",
"    If early glucocorticoid withdrawal is attempted, it seems prudent to only do so in those who have received lymphocyte depleting therapy with ATG and possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    although the data for alemtuzumab are limited (but not anti-interleukin 2 receptor antibodies) induction therapy and to aggressively monitor these patients, perhaps even with protocol biopsies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Late withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is less clear whether late withdrawal (greater than one year) should or should not be recommended. The failure of withdrawal in up to 40 percent of patients in most studies emphasizes the need for caution. Late withdrawal has been successfully performed in some centers, but its effect upon long-term allograft function and the risk of chronic rejection has not been conclusively evaluated. Several studies have also suggested that many patients do not obtain any substantial, clinically significant benefit by eliminating low-dose glucocorticoid therapy. In addition, methods of identifying candidates who will suffer adverse renal consequences from withdrawal are not available.",
"   </p>",
"   <p>",
"    Successful withdrawal protocols use a slow taper over a two to four month period. With stable patients, one successful regimen is to taper the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    by 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    every week until the dose is 5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which is then changed to 10 mg every other day with a weekly reduction of 1 mg every other day until the dose is completely tapered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/28\">",
"     28",
"    </a>",
"    ]. A second protocol reduces the dose every two weeks by 2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    until the prednisone dose is tapered to zero [",
"    <a class=\"abstract\" href=\"UTD.htm?21/4/21577/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that there is little long-term benefit and a small, but clear",
"    <strong>",
"     risk",
"    </strong>",
"    observed in patients withdrawn from small doses of glucocorticoids after one year. Patients chosen for glucocorticoid withdrawal at our center have a low-risk profile and an identifiable potential benefit for withdrawal. Thus, we have withdrawn glucocorticoids after one year in less than 1 percent of renal transplant patients at our center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glucocorticoid avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid avoidance may eventually be found to provide the best overall risk-to-benefit ratio with maintenance immunosuppressive therapy in renal transplantation. Glucocorticoid avoidance protocols have been used successfully and are presently undergoing extensive evaluation.",
"   </p>",
"   <p>",
"    However, many of these protocols, although not all, and other anecdotal reports have chosen low-risk individuals and utilized aggressive induction therapy. In addition, if decreases in the intensity of immunosuppression are needed in some patients with these regimens (consisting of dual therapy with a calcineurin-inhibitor and an antimetabolite) because of an infectious event or drug toxicity, the next alternative for maintenance immunosuppressive therapy is monotherapy. Currently, we cannot universally recommend glucocorticoid&ndash;free immunosuppressive regimens based on the best evidence-based data.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Brent LA. History of Transplantation Immunology, Academic Press, Boston 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/2\">",
"      STARZL TE, MARCHIORO TL, WADDELL WR. THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet 1963; 117:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/3\">",
"      Lemieux I, Houde I, Pascot A, et al. Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int 2002; 62:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/4\">",
"      Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994; 57:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/5\">",
"      Bodziak, KA, Hricik, DE. Minimizing the side effects of immunosuppression in kidney transplant recipients. Curr Opin Organ Transplant 2003; 8:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/6\">",
"      Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol 2003; 14:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/7\">",
"      Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6:1111.",
"     </a>",
"    </li>",
"    <li>",
"     www.ustransplant.org (Accessed on January 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/9\">",
"      Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004; 78:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/10\">",
"      Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11:1910.",
"     </a>",
"    </li>",
"    <li>",
"     Pascual, J, Zamora, J, Galeano, C, et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009; Jan 21:(1):CD005632.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/12\">",
"      Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/13\">",
"      Schold JD, Santos A, Rehman S, et al. The success of continued steroid avoidance after kidney transplantation in the US. Am J Transplant 2009; 9:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/14\">",
"      Pascual J, Royuela A, Galeano C, et al. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant 2012; 27:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/15\">",
"      KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl 3):S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/16\">",
"      Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/17\">",
"      Hricik DE, O'Toole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/18\">",
"      Sandrini S, Maiorca R, Scolari F, et al. A prospective randomized trial on azathioprine addition to cyclosporine versus cyclosporine monotherapy at steroid withdrawal, 6 months after renal transplantation. Transplantation 2000; 69:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/19\">",
"      Hricik DE, Knauss TC, Bodziak KA, et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003; 76:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/20\">",
"      Vanrenterghem Y, van Hooff JP, Squifflet JP, et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/21\">",
"      Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/22\">",
"      Boardman RE, Alloway RR, Alexander JW, et al. African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant 2005; 5:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/23\">",
"      Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/24\">",
"      Vanrenterghem Y, Lebranchu Y, Hen&eacute; R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/25\">",
"      Pascual J, van Hooff JP, Salmela K, et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006; 82:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/26\">",
"      Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/27\">",
"      Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010; 90:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/28\">",
"      Ratcliffe PJ, Dudley CR, Higgins RM, et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/29\">",
"      Hollander AA, Hene RJ, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/30\">",
"      Sivaraman P, Nussbaumer G, Landsberg D. Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am J Kidney Dis 2001; 37:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/31\">",
"      Opelz G, D&ouml;hler B, Laux G, Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005; 5:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/32\">",
"      Grinyo JM, Gil-Vernet S, Ser&oacute;n D, et al. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 1997; 63:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/33\">",
"      Smak Gregoor PJ, de S&eacute;vaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/34\">",
"      Rama I, Cruzado JM, Gil-Vernet S, et al. Steroids can be safely withdrawn from cyclosporine and mycophenolate mofetil-treated renal allograft recipients: long-term results. Transplantation 2005; 80:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/35\">",
"      Arnol M, de Mattos AM, Chung JS, et al. Late steroid withdrawal and cardiovascular events in kidney transplant recipients. Transplantation 2008; 86:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/36\">",
"      Hricik DE. Steroid withdrawal for the (selected) masses. Am J Transplant 2005; 5:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/37\">",
"      Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Preliminary results of a European multicentre trial. Lancet 1982; 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/38\">",
"      Birkeland SA. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 1998; 66:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/39\">",
"      Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 2001; 71:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/40\">",
"      Matas AJ, Ramcharan T, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001; 1:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/41\">",
"      Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005; 5:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/42\">",
"      Rizzari MD, Suszynski TM, Gillingham KJ, et al. Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol 2012; 7:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/43\">",
"      Augustine JJ, Hricik DE. Are maintenance corticosteroids no longer necessary after kidney transplantation? Clin J Am Soc Nephrol 2012; 7:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/44\">",
"      Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/45\">",
"      Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/46\">",
"      Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/47\">",
"      ter Meulen CG, van Riemsdijk I, Hen&eacute; RJ, et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 2004; 4:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/48\">",
"      Khwaja K, Asolati M, Harmon J, et al. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 2004; 4:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/49\">",
"      Borrows R, Loucaidou M, Van Tromp J, et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2004; 4:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/50\">",
"      Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/51\">",
"      Kumar, MS, et al. Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005; 5:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/52\">",
"      Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. Am J Transplant 2005; 5:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/53\">",
"      Anil Kumar MS, Heifets M, Fyfe B, et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005; 80:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/54\">",
"      V&iacute;tko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005; 80:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/55\">",
"      Kumar MS, Heifets M, Moritz MJ, et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 2006; 81:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/56\">",
"      Parrott NR, Hammad AQ, Watson CJ, et al. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. Transplantation 2005; 79:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/57\">",
"      Woodle ES, Vincenti F, Lorber MI, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 2005; 5:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/58\">",
"      Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006; 6:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/59\">",
"      Gallon LG, Winoto J, Leventhal JR, et al. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006; 1:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/60\">",
"      ter Meulen CG, van Riemsdijk I, Hen&eacute; RJ, et al. No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study. Transplantation 2004; 78:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/61\">",
"      Ibrahim H, Rogers T, Casingal V, et al. Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol. Transplantation 2006; 81:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/62\">",
"      Khwaja K, Asolati M, Harmon JV, et al. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation 2004; 78:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/63\">",
"      Anil Kumar MS, Moritz MJ, Saaed MI, et al. Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005; 5:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/64\">",
"      Anil Kumar MS, Khan S, Ranganna K, et al. Long-term outcome of early steroid withdrawal after kidney transplantation in African American recipients monitored by surveillance biopsy. Am J Transplant 2008; 8:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/65\">",
"      Humar A, Gillingham K, Kandaswamy R, et al. Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant 2007; 7:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/66\">",
"      Chhabra D, Skaro AI, Leventhal JR, et al. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Clin J Am Soc Nephrol 2012; 7:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/67\">",
"      Heilman RL, Younan K, Wadei HM, et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation 2011; 92:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/68\">",
"      Kukla A, Chen E, Spong R, et al. Recurrent glomerulonephritis under rapid discontinuation of steroids. Transplantation 2011; 91:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/69\">",
"      Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 2011; 11:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/70\">",
"      Hricik DE, Schulak JA. Steroid withdrawal from cyclosporine-based regimens: con--a flawed strategy. Transplant Proc 1998; 30:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/71\">",
"      Ponticelli C. Withdrawal of steroids from a cyclosporine-based regimen: pro. Transplant Proc 1998; 30:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/72\">",
"      European best practice guidelines for renal transplantation (Part 2). Nephrol Dial Transplant 2002; 17(Suppl 4):19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/4/21577/abstract/73\">",
"      Hricik DE. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant 2002; 2:19.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7319 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21577=[""].join("\n");
var outline_f21_4_21577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MINIMIZING GLUCOCORTICOID USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Very low dose maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Withdrawal several weeks to months after surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Withdrawal years after transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glucocorticoid-free regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39853556\">",
"      - Choice of immunosuppressive agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9604890\">",
"      Recurrent glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Glucocorticoid minimization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Withdrawal several months after surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Late withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glucocorticoid avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41111?source=related_link\">",
"      Withdrawal of immunosuppression after renal transplant failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_4_21578="Warfarin: Pediatric drug information";
var content_f21_4_21578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Warfarin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"    see \"Warfarin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"    see \"Warfarin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coumadin&reg;;",
"     </li>",
"     <li>",
"      Jantoven&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F234877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Warfarin&reg;;",
"     </li>",
"     <li>",
"      Coumadin&reg;;",
"     </li>",
"     <li>",
"      Mylan-Warfarin;",
"     </li>",
"     <li>",
"      Novo-Warfarin;",
"     </li>",
"     <li>",
"      Taro-Warfarin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticoagulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"      see \"Warfarin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing must be individualized.",
"     <b>",
"      Note:",
"     </b>",
"     New product labeling identifies genetic factors which may increase patient sensitivity to warfarin. Specifically, genetic variations in the proteins CYP2C9 and VKORC1, responsible for warfarin&rsquo;s primary metabolism and pharmacodynamic activity, respectively, have been identified as predisposing factors associated with decreased dose requirement and increased bleeding risk. A genotyping test is available and may provide important guidance on initiation of anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"     <b>",
"      To maintain an International Normalized Ratio (INR) between 2-3",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial loading dose on day 1 (if baseline INR is 1-1.3): 0.2 mg/kg (maximum dose: 10 mg); use initial loading dose of 0.1 mg/kg if patient has liver dysfunction or has undergone a Fontan procedure (Streif, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose for days 2-4: doses are dependent upon patient's INR",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is 1.1-1.3, repeat the initial loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is 1.4-1.9, give 50% of the initial loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is 2-3, give 50% of the initial loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is 3.1-3.5, give 25% of the initial loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is &gt;3.5, hold the drug until INR &lt;3.5, then restart at 50% of previous dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose guidelines for day 5 of therapy and beyond: Doses are dependent upon patient's INR",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is 1.1-1.4, increase dose by 20% of previous dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is 1.5-1.9, increase dose by 10% of previous dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is 2-3, do not change the dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is 3.1-3.5, decrease dose by 10% of previous dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     if INR is &gt;3.5, hold the drug and check INR daily until INR &lt;3.5, then restart at 20% less than the previous dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual maintenance dose: ~0.1 mg/kg/day; range: 0.05-0.34 mg/kg/day; the dose in mg/kg/day is inversely related to age. In the largest pediatric study (n=319; Streif, 1999), infants &lt;12 months of age required a mean dose of 0.33 mg/kg/day, but children 13-18 years required a mean dose of 0.09 mg/kg/day; a target INR of 2-3 was used for a majority of these patients (75% of warfarin courses). Overall, children required a mean dose of 0.16 mg/kg/day to achieve a target INR of 2-3. In another study (Andrew, 1994), to attain an INR of 1.3-1.8, infants &lt;12 months (n=2) required 0.24 and 0.27 mg/kg/day, but children &gt;1 year required a mean of 0.08 mg/kg/day (range: 0.03-0.17 mg/kg/day). Consistent anticoagulation may be difficult to maintain in children &lt;5 years of age. Children receiving phenobarbital, carbamazepine, or enteral nutrition may require higher maintenance doses (Streif, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Initial dosing must be individualized. Consider patient factors (hepatic function, cardiac function, age, nutritional status, concurrent therapy, risk of bleeding) in addition to prior dose response (if available) and the clinical situation. Initial dose: 2-5 mg daily for 2 days",
"     <b>",
"      or",
"     </b>",
"     5-10 mg daily for 1-2 days (Ansell, 2008); then adjust dose according to results of INR; usual maintenance dose ranges from 2-10 mg daily; individual patients may require loading and maintenance doses outside these general guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Lower starting doses may be required for patients with hepatic impairment, poor nutrition, CHF, elderly, high risk of bleeding, patients who are debilitated, or those with reduced function genomic variants of the catabolic enzymes CYP2C9 (*2 or *3 alleles) or VKORC1 (-1639 polymorphism); see table. Higher initial doses may be reasonable in selected patients (ie, receiving enzyme-inducing agents and with low risk of bleeding).",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Range",
"      <sup>",
"       1",
"      </sup>",
"      of Expected Therapeutic Maintenance Dose Based on CYP2C9",
"      <sup>",
"       2",
"      </sup>",
"      and VKORC1",
"      <sup>",
"       3",
"      </sup>",
"      Genotypes",
"     </caption>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Must also take into account other patient-related factors when determining initial dose (eg, age, body weight, concomitant medications, comorbidities)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Ranges derived from multiple published clinical studies.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 alleles may take up to 4 weeks to achieve maximum INR with a given dose regimen.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         VKORC1 -1639G&gt;A (rs 9923231) variant is used in this table; other VKORC1 variants may also be important determinants of dose.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          VKORC1",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          CYP2C9",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *1/*1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *1/*2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *1/*3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *2/*2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *2/*3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *3/*3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         GG",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-7 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-7 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         AG",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-7 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         AA",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     I.V.: (For patients who cannot take oral form): I.V. dose is equal to oral dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal disease:",
"     </b>",
"     No adjustment required; however, patients with renal failure have an increased risk of bleeding complications. Monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic disease:",
"     </b>",
"     Monitor effect at usual doses; the response to oral anticoagulants may be markedly enhanced in obstructive jaundice (due to reduced vitamin K absorption) and also in hepatitis and cirrhosis (due to decreased production of vitamin K-dependent clotting factors); INR should be closely monitored",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coumadin&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coumadin&reg;: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coumadin&reg;: 10 mg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jantoven&reg;: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jantoven&reg;: 10 mg [scored; dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088578.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088578.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer on an empty or full stomach. Take at the same time each day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: For I.V. use only; do not administer I.M. Reconstitute 5 mg vial with 2.7 mL SWI to produce 2 mg/mL solution. Administer by slow I.V. injection over 1-2 minutes into peripheral vein",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W,",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, ascorbic acid injection, bivalirudin, cefazolin, dopamine, epinephrine, heparin, lidocaine, morphine, nitroglycerin, oxytocin, potassium chloride, ranitidine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, ceftazidime, cimetidine, ciprofloxacin, dobutamine, esmolol, gentamicin, labetalol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ammonium chloride, ceftriaxone, metronidazole, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone, heparin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Dispense in tight, light-resistant container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Store unopened vials in box at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. After reconstitution, store at controlled room temperature and use within 4 hours after reconstitution. Do not refrigerate. Discard unused portion (does not contain preservative). Reconstituted solution is stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in LR, NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders; prevention and treatment of thromboembolic complications in patients with prosthetic heart valves or atrial fibrillation; reduction of the risk of death, recurrent MI, and thromboembolic events such as systemic embolization or stroke after MI; has also been used for the prevention of recurrent arterial ischemic stroke and TIAs.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Coumadin&reg; may be confused with Avandia&reg;, Cardura&reg;, Compazine, Kemadrin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Jantoven&reg; may be confused with Janumet&reg;, Januvia&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      National Patient Safety Goals:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Joint Commission on Accreditation of Healthcare Organizations requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F234922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleeding is the major adverse effect of warfarin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Signs/symptoms of bleeding (eg, dizziness, fatigue, fever, headache, lethargy, malaise, pain)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, bullous eruptions, dermatitis, rash, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, flatulence,  gastrointestinal bleeding, nausea, taste disturbance, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, retroperitoneal hematoma, unrecognized bleeding sites (eg, colon cancer) may be uncovered by anticoagulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis (including cholestatic hepatitis), transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Osteoporosis (potential association with long-term use), paralysis, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory tract bleeding, tracheobronchial calcification",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reaction, hypersensitivity/allergic reactions, skin necrosis, gangrene, &ldquo;purple toes&rdquo; syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to warfarin or any component; hemorrhagic tendencies or blood dyscrasias; recent or contemplated surgery of the CNS, eye, or traumatic surgery with large open wounds; active ulceration or overt bleeding of GI, GU, or respiratory tracts; CNS hemorrhage; cerebral aneurysms; dissecting aortic aneurysms; pericarditis and pericardial effusions; bacterial endocarditis; spinal puncture or other procedures with potential for uncontrollable bleeding; major regional or lumbar block anesthesia; neurosurgical procedures; malignant hypertension; pregnancy (except in women with mechanical heart valves who are at high risk for thromboembolism), threatened abortion, eclampsia, pre-eclampsia; inadequate laboratory facilities; unsupervised patients with conditions associated with a high potential for noncompliance",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not switch brands once desired therapeutic response has been achieved. Use with caution in patients with acute infection or active tuberculosis (antibiotics and fever may alter the response to warfarin), prolonged dietary insufficiencies (vitamin K deficiency), diabetes mellitus, thyroid disease, moderate-to-severe renal or hepatic impairment, or heparin-induced thrombocytopenia with deep vein thrombosis (limb ischemia, necrosis, and gangrene have occurred when warfarin was started or continued after heparin was stopped; warfarin monotherapy is contraindicated in the initial treatment of active HIT; warfarin initially inhibits the synthesis of protein C, potentially accelerating the underlying active thrombotic process). Use with caution in patients with or at risk for hemorrhage, necrosis, or gangrene. Use care in the selection of patients appropriate for this treatment; ensure patient cooperation especially from the alcoholic, illicit drug user, demented, or psychotic patient. Safety and efficacy have not been established in pediatric patients; monitor closely; rare hair loss and tracheal calcification have been reported  in children.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Periodic monitoring of INR (preferred) or prothrombin time is essential. A large number of factors (alone or in combination), including changes in diet, medications, and herbal remedies, may influence the patient's response to warfarin; monitor patients more closely when these factors change. Genetic variations in the CYP2C9 and vitamin K oxidoreductase (VKORC1) enzymes may also influence the patient&rsquo;s response to warfarin; presence of the CYP2C9*2 or *3 allele and/or polymorphism of the VKORC1 gene may increase the risk of bleeding. The *2 allele is reported to occur with a frequency of 4% to 11% in African-Americans and Caucasians, respectively, while the *3 allele frequencies are 2% to 7%, respectively. Other variant 2C9 alleles (eg, *5, *6, *9, and *11) are also associated with reduced metabolic activity and thus may increase risk of bleeding, but are much less common. Lower doses may be required in these patients; genetic testing may help determine appropriate dosing.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Serious and potentially fatal bleeding may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Bleeding is more likely during initiation of treatment (within first month) and with higher doses. Risk factors for bleeding include high intensity anticoagulation (INR &gt;4), age (&ge;65 years), highly variable INRs, history of GI bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, severe diabetes, malignancy, trauma, renal insufficiency, polycythemia vera, vasculitis, open wound, history of PUD, indwelling catheters, menstruating and postpartum women, drug-drug interactions, and long duration of therapy. Regular monitoring of INR is required",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Dosage must be individualized for each patient. Medications, dietary changes, and other factors affect INR levels achieved with warfarin therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Patients must be instructed about preventative measures to minimize risk of bleeding and to report bleeding, accidents, or falls as well as any new or discontinued medications, herbal, or alternative products used, or significant changes in smoking or dietary habits",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Necrosis and/or gangrene of the skin and other tissues may occur (rarely) due to early hypercoagulability; risk is increased in patients with protein C deficiency; tissue debridement or amputation may be required; permanent disability or death has been reported; discontinue warfarin if warfarin-associated necrosis occurs; consider heparin for anticoagulation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Warfarin therapy may release atheromatous plaque emboli; symptoms depend on site of embolization, most commonly kidneys, pancreas, liver, and spleen. In some cases, emboli may lead to necrosis or death. \"Purple toe\" syndrome, due to cholesterol microembolization, has been rarely described with coumarin-type anticoagulants. Typically, this occurs after several weeks of therapy, and may present as a dark, purplish, mottled discoloration of the plantar and lateral surfaces. Other manifestations of cholesterol microembolization may include rash; livedo reticularis; gangrene; abrupt and intense pain in lower extremities; abdominal, flank, or back pain; hematuria; renal insufficiency; hypertension; cerebral ischemia; spinal cord infarction; or other symptoms of vascular compromise.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hypersensitivity reactions, including anaphylaxis; use with caution in patients with anaphylactic disorders. Concomitant use with vitamin K may decrease anticoagulant effect; monitor carefully. Concomitant use with ethacrynic acid, indomethacin, NSAIDs, phenylbutazone, or aspirin increases warfarin's anticoagulant effect and may cause severe GI irritation. Oral anticoagulant therapy is usually avoided in neonates due to a greater potential risk of bleeding (Monagle, 2001) and other problems (Monagle, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F234911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adalimumab: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Androgens: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents: May enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Alitretinoin; Altretamine; Aminoglutethimide; Anastrozole; Asparaginase (E. coli); Asparaginase (Erwinia); AzaCITIDine; Bleomycin; Capecitabine; CARBOplatin; Carmustine; Chlorambucil; CISplatin; Cladribine; Cytarabine (Conventional); Cytarabine (Liposomal); Dacarbazine; DACTINomycin; DAUNOrubicin (Conventional); DAUNOrubicin (Liposomal); Denileukin Diftitox; DOCEtaxel; DOXOrubicin (Liposomal); EPIrubicin; Estramustine; Etoposide Phosphate; Exemestane; Fludarabine; Goserelin; Hydroxyurea; IDArubicin; Irinotecan; Letrozole; Leuprolide; Lomustine; Mechlorethamine; Megestrol; MitoMYcin (Systemic); MitoXANtrone; Nilutamide; PACLitaxel; Pegaspargase; Pentostatin; Polyestradiol; Porfimer; RiTUXimab; Streptozocin; Tamoxifen; Temozolomide; Teniposide; Thioguanine; Thiotepa; Topotecan; Toremifene; Tretinoin (Systemic); Valrubicin; VinBLAStine; Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antithyroid Agents: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bicalutamide: May increase the serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Warfarin. Boceprevir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capecitabine: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloral Hydrate: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coenzyme Q-10: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products. Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cranberry: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desvenlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dicloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Vitamin K Antagonists may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received oral anticoagulants within 1 week or have INR 3 or greater.  Monitor for bleeding and immediately stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Vitamin K Antagonists. Efavirenz may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Warfarin. More specifically, enzalutamide may decrease concentrations of the S-warfarin enantiomer. Management: Avoid concurrent use of warfarin and enzalutamide whenever possible.  If the combination must be used, conduct additional INR monitoring as serum concentrations may be decreased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Ophthalmic): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Esomeprazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethacrynic Acid: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethotoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Ethotoin. Management: Anticoagulant dose adjustment will likely be necessary when ethotoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the anticoagulant effect of Warfarin. Fenofibrate may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the anticoagulant effect of Warfarin. Fenofibric Acid may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenugreek: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Warfarin. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the adverse/toxic effect of Vitamin K Antagonists. Management: Consider avoiding the use of this combination of agents. Monitor for signs and symptoms of bleeding if vitamin K antagonists and Ginkgo biloba are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginseng (American): May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucagon: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glutethimide: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May enhance the adverse/toxic effect of Vitamin K Antagonists. Particularly, the risk of bleeding may be increased due to possible antiplatelet effects of green tea. Green Tea may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May enhance the anticoagulant effect of Warfarin. Imatinib may decrease the metabolism of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivermectin (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lansoprazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives to concomitant therapy with these agents.  Monitor for increased INR/bleeding risk if metronidazole is initiated/dose increased, or decreased effects if metronidazole is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miconazole (Topical): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Milnacipran: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the anticoagulant effect of Vitamin K Antagonists. Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May decrease the serum concentration of Warfarin. Nelfinavir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neomycin: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the anticoagulant effect of Vitamin K Antagonists. NSAID (COX-2 Inhibitor) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phytonadione: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: Warfarin may enhance the adverse/toxic effect of Regorafenib. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: May enhance the therapeutic effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Salsalate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sitaxentan: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May enhance the anticoagulant effect of Warfarin. SORAfenib may increase the serum concentration of Warfarin. Management: Warfarin dose adjustment will likely be necessary.  Increase frequency of INR monitoring during sorafenib therapy (particularly when starting or stopping therapy), and increase monitoring for signs and symptoms of bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists. Management: Administer vitamin K antagonists at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfinpyrazone [Off Market]: May decrease the metabolism of Vitamin K Antagonists. Sulfinpyrazone [Off Market] may decrease the protein binding of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Warfarin. Telaprevir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tigecycline: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Torsemide: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: May diminish the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vorinostat: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zafirlukast: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zileuton: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1056057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin K can reverse the anticoagulation effects of warfarin; large amounts of food high in vitamin K (such as beef liver, pork liver, green tea, and green leafy vegetables) may reverse warfarin, decrease prothrombin time, and lead to therapeutic failure. Patients should not change dietary habits once stabilized on warfarin therapy. A balanced diet with a consistent intake of vitamin K is essential. Avoid large amounts of alfalfa, asparagus, broccoli, brussel sprouts, cabbage, cauliflower, green teas, kale, lettuce, spinach, turnip greens, watercress. Avoid enteral feeds high in vitamin K.",
"     <b>",
"      Note:",
"     </b>",
"     Breast-fed infants may be more sensitive to warfarin due to low amounts of vitamin K in breast milk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     High doses of vitamin A, E, or C may alter PT; use caution with fish oils or omega 3 fatty acids; avoid fried or boiled onions as they may increase drug effect by increasing fibrinolytic activity; avoid herbal teas and remedies such as tonka beans, melilot, and woodruff as they contain natural coumarins and will increase effect of warfarin; avoid large amounts of liver, avocado, soy protein, soybean oil, papain.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cranberry juice or other cranberry products may increase the INR in patients receiving warfarin and cause severe bleeding (flavonoids found in cranberries may inhibit cytochrome P450 isoenzyme CYP2C9 and reduce the metabolism of warfarin)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (women with mechanical heart valves)/X (other indications) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F234859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Warfarin crosses the placenta; concentrations in the fetal plasma are similar to maternal values. Teratogenic effects have been reported following first trimester exposure and may include coumarin embryopathy (nasal hypoplasia and/or stippled epiphyses; limb hypoplasia may also be present). Adverse CNS events to the fetus have also been observed following exposure during any trimester and may include CNS abnormalities (including ventral midline dysplasia, dorsal midline dysplasia). Spontaneous abortion, fetal hemorrhage, and fetal death may also occur. Use is contraindicated during pregnancy (or in women of reproductive potential) except in women with mechanical heart valves who are at high risk for thromboembolism; use is also contraindicated in women with threatened abortion, eclampsia, or preeclampsia. Frequent pregnancy tests are recommended for women who are planning to become pregnant and adjusted-dose heparin or low molecular weight heparin (LMWH) should be substituted as soon as pregnancy is confirmed or adjusted-dose heparin or LMWH should be used instead of warfarin prior to conception.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In pregnant women with high-risk mechanical heart valves, the benefits of warfarin therapy should be discussed with the risks of available treatments; when possible avoid warfarin use during the first trimester and close to delivery. Adjusted-dose LMWH or adjusted-dose heparin may be used throughout pregnancy or until week 13 of gestation when therapy can be changed to warfarin. LMWH or heparin should be resumed close to delivery. In women who are at a very high risk for thromboembolism (older generation prothesis in mitral position or history of thromboembolism), warfarin can be used throughout pregnancy and replaced with LMWH or heparin near term; the use of low-dose aspirin is also recommended. Women who require long-term anticoagulation with warfarin and who are considering pregnancy, LMWH substitution should be done prior to conception when possible. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Bates, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     INR (preferred) or prothrombin time; hemoglobin, hematocrit, signs and symptoms of bleeding; consider genotyping of CYP2C9 and VKORC1 prior to initiation of therapy, if available.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The INR is now the standard test used to monitor warfarin anticoagulation; the desired INR is based upon indication; due to the lack of pediatric clinical trials assessing optimal INR ranges and clinical outcomes, the desired INR ranges for children are extrapolated from adult studies; the optimal therapeutic INR ranges may possibly be lower in children versus adults. Further pediatric studies are needed (Monagle, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     If INR is not available, prothrombin time should be 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     to 2 times the control.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Targeted INR and Ranges for Children, Based on Indication",
"      <sup>",
"       a,b,c",
"      </sup>",
"     </caption>",
"     <col align=\"left\" width=\"300\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Indication",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Targeted INR",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Targeted INR Range",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          a",
"         </sup>",
"         Information from Monagle, 2004 and Monagle, 2008.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          b",
"         </sup>",
"         Children are defined in the Chest guidelines as patients aged 28 days to 16 years of age.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          c",
"         </sup>",
"         See Monagle, 2008 for timing of initiation and adjunct antithrombotic and antiplatelet therapy.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          d",
"         </sup>",
"         Anticoagulant therapy with UFH or LMWH is recommended for children with first episode of venous thromboembolism (central venous line and noncentral venous line related).",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Systemic venous thromboembolism",
"         <sup>",
"          d",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Central venous line-related thrombosis, initial 3 months of therapy",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Central venous line-related thrombosis after first 3 months of warfarin therapy (",
"         <b>",
"          Note:",
"         </b>",
"         This is a prophylactic dose)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.5-1.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Central venous line, long-term home TPN (prophylactic dose) (Not recommended routinely)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Primary prophylaxis following Fontan procedure",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Primary prophylaxis for dilated cardiomyopathy",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Primary prophylaxis for biological prosthetic heart valves in children",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Follow adult guidelines in table below",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Primary prophylaxis for mechanical prosthetic heart valves in children",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Follow adult guidelines in table below",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Kawasaki disease with giant coronary aneurysms",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cerebral sinovenous thrombosis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         INR recommendations from 2004 Chest guidelines",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Adult Target INR Ranges Based Upon Indication",
"     </caption>",
"     <col align=\"left\" width=\"300\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Indication",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Targeted INR",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Targeted INR Range",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          a",
"         </sup>",
"         High-risk includes large anterior MI, significant heart failure, intracardiac thrombus, atrial fibrillation, history of thromboembolism.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          b",
"         </sup>",
"         Maintain anticoagulation for 3 months.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          c",
"         </sup>",
"         Combine with aspirin 81 mg/day.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          d",
"         </sup>",
"         Combine with aspirin 81 mg/day, if not previously receiving,",
"         <b>",
"          and/or",
"         </b>",
"         if previous target INR was 2.5, then new target INR should be 3 (2.5-3.5). If previous target INR was 3, then new target INR should be 3.5 (3-4).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          e",
"         </sup>",
"         MI refers to anterior-apical ST-segment elevation myocardial infarction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          f",
"         </sup>",
"         Combine with aspirin 81 mg/day unless patient is at high risk of bleeding (eg, history of GI bleed, age &gt;80 years).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          g",
"         </sup>",
"         Maintain anticoagulation for 3 months after valve insertion, then switch to aspirin 81 mg/day if no other indications for warfarin exist or clinically reassess need for warfarin in patients with prior history of systemic embolism.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          h",
"         </sup>",
"         Maintain anticoagulation with warfarin until thrombus resolution.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          i",
"         </sup>",
"         If patient has history of atherosclerotic vascular disease, combine with aspirin 81 mg/day unless patient is at high risk of bleeding (eg, history of GI bleed, age &gt;80 years).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          j",
"         </sup>",
"         Treat for 3 months in patients with VTE due to transient reversible risk factor. Treat for a minimum of 3 months in patients with unprovoked VTE and evaluate for long-term therapy. Other risk groups (eg, cancer) may require &gt;3 months of therapy.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          k",
"         </sup>",
"         In patients with unprovoked VTE who prefer less frequent INR monitoring, low-intensity therapy (INR range: 1.5-1.9) with less frequent monitoring is recommended over stopping treatment.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          l",
"         </sup>",
"         Continue for at least 10 days and up to 35 days after surgery.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          m",
"         </sup>",
"         Continue for up to 12 months.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Cardiac",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Acute myocardial infarction (high risk)",
"         <sup>",
"          a",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"         <sup>",
"          b,c",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Atrial fibrillation or atrial flutter",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Valvular",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Bileaflet or Medtronic Hall tilting disk mechanical aortic valve in normal sinus rhythm and normal LA size",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Bileaflet or tilting disk mechanical mitral valve",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-3.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Caged ball or caged disk mechanical valve",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-3.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Mechanical prosthetic valve with systemic embolism despite adequate anticoagulation",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"         <b>",
"          or",
"         </b>",
"         3.5",
"         <sup>",
"          d",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-3.5",
"         <sup>",
"          d",
"         </sup>",
"         <b>",
"          or",
"         </b>",
"         3-4",
"         <sup>",
"          d",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Mechanical valve and risk factors for thromboembolism (eg, AF, MI",
"         <sup>",
"          e",
"         </sup>",
"         , LA enlargement, hypercoagulable state, low EF) or history of atherosclerotic vascular disease",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-3.5",
"         <sup>",
"          f",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Bioprosthetic mitral valve",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"         <sup>",
"          g",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Bioprosthetic mitral or aortic valve with prior history of systemic embolism",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"         <sup>",
"          g",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Bioprosthetic mitral or aortic valve with evidence of LA thrombus at surgery",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"         <sup>",
"          h",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Bioprosthetic mitral or aortic valve with risk factors for thromboembolism (eg, AF, hypercoagulable state or low EF)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"         <sup>",
"          i",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Prosthetic mitral valve thrombosis (resolved)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.5-4.5",
"         <sup>",
"          c",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Prosthetic aortic valve thrombosis (resolved)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4",
"         <sup>",
"          c",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Rheumatic mitral valve disease and normal sinus rhythm (LA diameter &gt;5.5 cm), AF, previous systemic embolism, or LA thrombus",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Thromboembolism Treatment",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Venous thromboembolism",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"         <sup>",
"          j,k",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Thromboprophylaxis",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Chronic thromboembolic pulmonary hypertension (CTPH)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Lupus inhibitor (no other risk factors)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Lupus inhibitor and recurrent thromboembolism",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-3.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Major trauma patients with impaired mobility undergoing rehabilitation",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Spinal cord injury (acute) undergoing rehabilitation",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Total hip or knee replacement (elective) or hip fracture surgery",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"         <sup>",
"          l",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Other Indications",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cerebral venous sinus thrombosis",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"         <sup>",
"          m",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ischemic stroke due to AF",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     Warfarin levels are not used for monitoring degree of anticoagulation. They may be useful if a patient with unexplained coagulopathy is using the drug surreptitiously or if it is unclear whether clinical resistance is due to true drug resistance or lack of drug intake.",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     Normal prothrombin time (PT): 10.9-12.9 seconds. Healthy premature newborns have prolonged coagulation test screening results (eg, PT, aPTT, TT) which return to normal adult values at approximately 6 months of age. However, healthy premature newborns (ie, those not receiving antithrombotic agents), do not develop spontaneous hemorrhage or thrombotic complications because of a balance between procoagulants and inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with hepatic synthesis of vitamin K-dependent coagulation factors (II, VII, IX, X). Hepatic synthesis of coagulation factors II, VII, IX, and X, as well as proteins C and S, requires the presence of vitamin K. These clotting factors are biologically activated by the addition of carboxyl groups to key glutamic acid residues within the proteins&rsquo; structure. In the process, &ldquo;active&rdquo; vitamin K is oxidatively converted to an &ldquo;inactive&rdquo; form, which is then subsequently re-activated by vitamin K epoxide reductase complex 1 (VKORC1). Warfarin competitively inhibits the subunit 1 of the multi-unit VKOR complex, thus depleting functional vitamin K reserves and hence reduces synthesis of active clotting factors. The degree of warfarin&rsquo;s effect depends upon the dosage administered and, in part, by the patient&rsquo;s VKORC1 genotype.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticoagulation effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 24-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of action (single dose): 2-5 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.14 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily via CYP2C9; minor pathways include CYP2C19, 1A2, and 3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genomic variants: Clearance of S-warfarin is reduced by ~37% in patients heterozygous for 2C9 (*1/*2 or *1/*3), and reduced by ~70% in patients homozygous for reduced function alleles (*2/*2, *2/*3, or *3/*3)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: Adults: 20-60 hours; mean: 40 hours; highly variable among individuals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (92%, primarily as metabolites; very little warfarin is excreted unchanged in the urine)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"      see \"Warfarin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of warfarin. Take exactly as directed; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose. Follow diet and activity as recommended by prescriber; check with prescriber before changing diet. Do not make major changes in your dietary intake of vitamin K (green leafy vegetables). Avoid alcohol, cranberry juice, and cranberry products; limit caffeine. Report any signs of bleeding to physician at once (eg, nosebleeds, bleeding gums, prolonged bleeding from a cut, heavier than normal menstrual or vaginal bleeding, coughing up blood, vomiting blood or coffee ground-like material, pink or dark brown urine, red or black tar-like stools, unusual bruising, headaches, dizziness, weakness, pain, swelling, or discomfort). Avoid hazardous activities; use soft toothbrush; carry medical identification indicating warfarin use (eg, medical alert ID bracelet or medication card). Be aware of other drugs, foods, and herbal remedies to avoid. Report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. Do not take any new medication during therapy unless approved by prescriber. Report adverse effects such as skin rash or irritation, unusual fever, persistent nausea or GI upset, pain in joints or back, or unhealed wounds.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usual duration of therapy in children (Monagle, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DVT:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Idiopathic TE: &ge;6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Recurrent idiopathic TE: Indefinite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Secondary thrombosis (with resolved risk factors): &ge;3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Recurrent secondary TE:  Anticoagulate until removal of precipitating factor (&ge;3 months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primary prophylaxis for Glenn or Bilateral Cavopulmonary Shunts (BCPS): Continue until ready for Fontan surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Post-Fontan surgery: Optimal duration not defined",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiomyopathy in children eligible for transplant: Until transplant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primary pulmonary hypertension: Duration not listed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Biological prosthetic heart valves: Follow adult recommendations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mechanical prosthetic heart valves: Follow adult recommendations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ventricular assist device (VAD) placement: Until transplant or weaned from VAD",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kawasaki disease: Treatment  depends on severity of coronary involvement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cerebral sinovenous thrombosis (CSVT) in neonates: 6 weeks-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CSVT in children: &ge;3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neonates with homozygous protein C deficiency: Long-term",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Overdoses of warfarin may be treated with vitamin K, to reverse warfarin's anticoagulation effect. Prospective genotyping is available and may provide important guidance on initiation of anticoagulant therapy. Commercial testing with PGxPredict&trade;:WARFARIN is now available from PGxHealth&trade; (Division of Clinical Data, Inc, New Haven, CT). The test genotypes patients for presence of the CYP2C9*2 or *3 alleles and the VKORC1 -1639G&gt;A polymorphism. The results of the test allow patients to be phenotyped as extensive, intermediate, or poor metabolizers (CYP2C9) and as low, intermediate, or high warfarin sensitivity (VKORC1). Ordering information is available at 888-592-7327 or warfarininfo@pgxhealth.com.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andrew M, Marzinotto V, Brooker LA, et al, &ldquo;Oral Anticoagulation Therapy in Pediatric Patients: A Prospective Study,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 1994, 71(3):265-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/8029786/pubmed\" id=\"8029786\" target=\"_blank\">",
"        8029786",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ansell J, Hirsh J, Poller L, et al, \"The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2004, 126(3 Suppl):204S-33S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/15383473/pubmed\" id=\"15383473\" target=\"_blank\">",
"        15383473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arepally GM and Ortel TL, \"Clinical Practice. Heparin-Induced Thrombocytopenia,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(8):809-17",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/16928996/pubmed\" id=\"16928996\" target=\"_blank\">",
"        16928996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      David M and Andrew M, &ldquo;Venous Thromboembolic Complications in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(3):337-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/8355108/pubmed\" id=\"8355108\" target=\"_blank\">",
"        8355108",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD &ldquo;Aiming for Safe Anticoagulation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(1):54-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/7776998 /pubmed\" id=\"7776998 \" target=\"_blank\">",
"        7776998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsh J, Dalen JE, Anderson DR, et al, &ldquo;Oral Anticoagulants. Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2001, 119:8S-21S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/ 11157640 /pubmed\" id=\" 11157640 \" target=\"_blank\">",
"        11157640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chalmers E, Chan A, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):887S-968S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/18574281/pubmed\" id=\"18574281\" target=\"_blank\">",
"        18574281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chan A, Massicotte P, et al, \"Antithrombotic Therapy in Children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2004, 126(3 Suppl):645S-87S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/15383489/pubmed\" id=\"15383489\" target=\"_blank\">",
"        15383489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Michelson AD, Bovill E, et al, &ldquo;Antithrombotic Therapy in Children,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2001, 119:344S-70S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/ 11157659 /pubmed\" id=\" 11157659 \" target=\"_blank\">",
"        11157659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salem DN, O'Gara PT, Madias C, et al, \"Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):593S-629S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/18574274/pubmed\" id=\"18574274\" target=\"_blank\">",
"        18574274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salem DN, Stein PD, Al-Ahmad A, et al, \"Antithrombotic Therapy in Valvular Heart Disease - Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2004, 126(3 Suppl):457S-82S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/15383481/pubmed\" id=\"15383481\" target=\"_blank\">",
"        15383481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Streif W, Andrew M, Marzinotto V, et al, \"Analysis of Warfarin Therapy in Pediatric Patients: A Prospective Cohort Study of 319 Patients,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 1999, 94(9):3007-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/10556183/pubmed\" id=\"10556183\" target=\"_blank\">",
"        10556183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suvarna R, Pirmohamed M, and Henderson L, \"Possible Interaction Between Warfarin and Cranberry Juice,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2003, 327(7429):1454.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/14684645/pubmed\" id=\"14684645\" target=\"_blank\">",
"        14684645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells PS, Holbrook AM, Crowther NR, et al, &ldquo;Interactions of Warfarin With Drugs and Food,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 121(9):676-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/4/21578/abstract-text/7944078/pubmed\" id=\"7944078\" target=\"_blank\">",
"        7944078",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12886 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21578=[""].join("\n");
var outline_f21_4_21578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708848\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234876\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234877\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056045\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056037\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234849\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234833\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874933\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056050\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234923\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056040\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056049\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234925\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234922\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056054\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056036\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056035\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234911\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234842\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056057\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234845\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234859\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056044\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056048\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056034\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056052\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056053\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056042\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056055\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12886\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12886|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=related_link\">",
"      Warfarin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=related_link\">",
"      Warfarin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_4_21579="Risk factors VTE genetic";
var content_f21_4_21579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic and acquired risk factors for a first episode of venous thrombosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition/risk factor(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence, percent per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin gene mutation",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor V Leiden (heterozygous)",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives plus heterozygous factor V Leiden",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        0.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor V Leiden (homozygous)",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        0.5 to 1.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Adult subjects only.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: the Leiden Thrombophilia Study.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21579=[""].join("\n");
var outline_f21_4_21579=null;
var title_f21_4_21580="Betamethasone vs dexamethasone";
var content_f21_4_21580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67486%7EOBGYN%2F80060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67486%7EOBGYN%2F80060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative risk of selected adverse outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Betamethasone versus control",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dexamethasone versus control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory distress syndrome",
"       </td>",
"       <td>",
"        0.57*",
"       </td>",
"       <td>",
"        0.70*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraventricular hemorrhage",
"       </td>",
"       <td>",
"        0.27*",
"       </td>",
"       <td>",
"        0.60*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perinatal infection",
"       </td>",
"       <td>",
"        0.72",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal death",
"       </td>",
"       <td>",
"        0.47*",
"       </td>",
"       <td>",
"        0.84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stillbirth",
"       </td>",
"       <td>",
"        0.80",
"       </td>",
"       <td>",
"        0.95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal infection",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.17",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Difference between study drug and controls was statistically significant.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Jobe, AH, Soll, RF. Am J Obstet Gynecol 2004; 190:878.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Odds ratio of selected adverse outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Betamethasone versus control",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dexamethasone versus control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraventricular hemorrhage",
"       </td>",
"       <td>",
"        0.63*",
"       </td>",
"       <td>",
"        0.76*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal death",
"       </td>",
"       <td>",
"        0.44*",
"       </td>",
"       <td>",
"        0.73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periventricular leukomalacia",
"       </td>",
"       <td>",
"        0.67",
"       </td>",
"       <td>",
"        0.63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinopathy of prematurity",
"       </td>",
"       <td>",
"        1.16",
"       </td>",
"       <td>",
"        1.12",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Difference between study drug and controls was statistically significant.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lee, BH, Stoll, BJ, McDonald, SA, et al. Pediatrics 2006; 117:1503.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21580=[""].join("\n");
var outline_f21_4_21580=null;
var title_f21_4_21581="UDCA and survival in PBC";
var content_f21_4_21581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Ursodeoxycholic acid slows disease progression in primary biliary cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 254px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of ursodeoxycholic acid (UDCA) on progression to liver transplantation or death in primary biliary cirrhosis. Patients were randomized to UDCA (dashed line) or placebo (solid line) for the first 24 months and then all patients were treated with UDCA for the next 24 months. The relative risk for liver transplantation or death was 0.32 in patients treated with UDCA throughout the study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group, N Engl J Med 1994; 330:1342.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21581=[""].join("\n");
var outline_f21_4_21581=null;
var title_f21_4_21582="Causes of cardiomyopathy II";
var content_f21_4_21582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologic classification of cardiomyopathy-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Genetic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Genetic hypertrophic cardiomyopathy*&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Genetic dilated cardiomyopathy&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Endocrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acromegaly*&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thyrotoxicosis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypothyroidism*&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pheochromocytoma*&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diabetes melllitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Familial storage diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Glycogen storage diseases*&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Refsum disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Niemann-Pick disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hand-Schuller-Christian disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fabry's disease*&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gangliosiderosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gaucher's disease&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sandhoff's disease&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mucopolysaccharidosis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hunter's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hurler's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Nutritional",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Beriberi&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Kwashiokor&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pellagra",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Selenium deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            (Keshan's disease)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypokalemia&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carnitine deficiency&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Uremia&Delta;",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hematologic/oncologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Hematologic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leukemia&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Myeloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sickle cell anemia&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anemia&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Henoch-Schonlein purpura&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Neoplastic diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Primary neoplasms&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Metastatic neoplasms&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Deposits",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemochromatosis&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oxalosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ochronosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amyloid disease&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Heredofamilial neurologic and neuromuscular diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Progressive muscular dystrophy (Duchenne)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Limb-girdle muscular dystrophy (Erb)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fascioscapulohumeral dystrophy (Landouzy-Dejerine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Humeroperoneal ataxia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Friedreich's ataxia*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myotonia atrophica (Steinert)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myasthenia gravis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic progressive external opthmoplegia (Kearns-Savre)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial centronuclear myopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Juvenile progressive spinal muscular atrophy (Kugelberg-Welander)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurofibromatosis*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endomyocardial diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endomyocardial fibrosis&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypereosiinophilic heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            (Loffler's)&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endocardial fibroelastosis&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inflammatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Connective tissue diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rheumatoid heart disease&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ankylosing spondylitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Systemic lupus erythematosus&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Scleroderma&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dermatomyositis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Periarteritis nodosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Granulomatous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoid&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Wegener's granulomatosis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Granulomatous myocarditis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other inflammation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Giant cell myocarditis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypersensitivity myocarditis&Delta;",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Conditions that may manifest clinically as hypertrophic cardiomyopathy. (These designations are neither obligatory nor exclusive.)",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Conditions that may manifest clinically as restrictive cardiomyopathy.",
"      <br>",
"       &Delta; Conditions that may manifest clinically as dilated cardiomyopathy.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Abelmann WH. Introduction to Atlas of Heart Diseases, Vol. II: Cardiomyopathies, Myocarditis and Pericardial disease, Abelmann, WH (Ed), Current Medicine, Philadelphia, 1995, p.1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21582=[""].join("\n");
var outline_f21_4_21582=null;
var title_f21_4_21583="Moderate fluorosis";
var content_f21_4_21583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moderate fluorosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These incisors with moderate fluorosis have an opaque white appearance and a round lesion where hypomineralized enamel has been abraded from the surface during normal function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:975. Copyright &copy; WB Saunders 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_4_21583=[""].join("\n");
var outline_f21_4_21583=null;
